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1CHAPTER 1.  GENERAL INTRODUCTION
Organic chemistry is a science central to interdisciplinary research between fields
such as molecular biology and medicinal chemistry. Knowledge of natural product
structures and an understanding of how these structures interact with biomolecules can
lead to valuable therapeutics.
Central to this study is the synthesis of natural products and natural product
derivatives with the goal of discovering structures that are most beneficial at inhibiting
diseases, particularly HIV-1. The synthetic approaches incorporate environmentally
benign methodologies, regioselective reactions and key intermediates that can be easily
elaborated into a diverse set of analogues valuable for structure-activity relationship
studies.
2CHAPTER 2: SYNTHESIS OF 1,7-DIOXYGENATED XANTHONE NATURAL
PRODUCTS
INTRODUCTION
Xanthone (from the Greek, meaning yellow) is the chemical compound dibenzo-
γ-pyrone (Figure 1).1 There are nearly one thousand known naturally-occurring
derivatives.2-4 In a literature survey covering naturally occurring xanthones from January
2000 to December 2004, Vieira and Kijjoa reported 278 new xanthones.5 In a survey
covering 2005-2008, El-Seedi reported 122 new natural xanthones.6 Xanthones are
secondary plant metabolites that have been isolated from higher plant families, fungi and
lichens. The families Clusiaceae and Gentianaceae are the major sources. Xanthones
attract considerable interest because of their taxonomic importance in some families7 and
because of their potential as therapeutic agents.8
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Figure 1.  Xanthone nucleus and numbering.
ISOLATION
All parts of the plant can contain xanthones, which can be extracted with organic
solvents and then separated by chromatography on silica gel or HPLC.3 After separation,
xanthones have been identified by comparison with authentic samples by TLC.
Determining the structure of naturally occurring xanthones is most commonly
accomplished from the 1H NMR, 13C NMR, UV, IR, and MS data. In 2004, Bo and Liu
3emphasized capillary electrophoresis in a review of methods used to separate
pharmacologically active xanthones.9 Bioactive xanthones have also been isolated by
bioassay-guided fractionation methods by monitoring biological activities, including:
antibacterial,10 antifungal,11 antiviral,12,13 trypanocidal,14,15 and cytotoxic activities against
human carcinoma cell lines.13-15
CLASSIFICATION
Xanthones can be classified into six main groups: simple oxygenated xanthones,
xanthone glycosides, prenylated xanthones, xanthonolignoids, bis-xanthones, and
miscellaneous xanthones. The main groups are subdivided according to the degree of
oxygenation into non-, mono-, di-, tri-, tetra-, penta-, and hexaoxygenated xanthones.
Simple xanthones contain simple substituents such as hydroxy, methoxy or methyl.
Simple nonoxygenated xanthones
Xanthone (1) and methylxanthones (2-5) (Figure 2) were observed in crude oils
from off-shore Norway and reported by Oldenburg and co-workers in 2002.19 This was
the first description of xanthones in fossil organic matter. Formation of these compounds
may have occurred by diagenetic products, oxidation of xanthenes in the reservoir, or by
geosynthesis from aromatic precursors.
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Figure 2.  Nonoxygenated xanthones from crude oils
4Simple monooxygenated xanthones
This class of xanthones has few naturally occurring members. 3-(2-
Hydroxyethoxy)-xanthone (6)20 and 2-carbomethoxy-6-methoxyxanthone (7)21 (Figure 3)
are examples from Hedychium gardnerianum and Calophyllum teysmannii var.
inophylloide, respectively. Xanthone 8 is a phytotoxic compound isolated from the
fungus Guanomyces polythrix.22
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Figure 3. Monooxygenated xanthones
Simple dioxygenated xanthones
Dioxygenated xanthones are more common. Among examples are euxanthone (9)
and 1-methoxy-7-hydroxyxanthone (10) found in Hypericum perforatum (Figure 4).23
O
O
9
OH
OH
O
O
10
OMe
OH
Figure 4. Dioxygenated xanthones from Hypericum perforatum
Simple trioxygneated xanthones
There are more examples of trioxygenated xanthones than there are of
dioxygenated xanthones. The first xanthone ever isolated—gentisine, 1,7-dihydroxy-3-
methoxyxanthone24—is trioxygenated. Another example is 1,3-dihydroxy-5-
methoxyxanthone-4-sulfonate (11) (Figure 11), which was isolated from Hypericum
5sampsonii in 2004.25 This sulfonated xanthone was cytotoxic against the P388 (mouse
lymphocytic leukemia) cancer cell line. Cratoxyarborenone F (12) is another xanthone
isolated from Hypericum perforatum.23 Compound 12 possessed moderate cytotoxicity
toward a human oral epidermoid carcinoma (KB) cancer cell line.26
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Figure 5.  Cytotoxic trioxygenated xanthones from Hypericum
Simple tetraoxygenated xanthones
There are more examples of tetraoxygenated xanthones than there are of
trioxygenated xanthones. Three tetraoxygentated xanthones (13, 14 and 15) (Figure 6)
were isolated from Leiothrix curvifolia and Leiothrix flavenscens, herbaceous
monocotyledons native to Brazil.71
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Figure 6.  Tetaoxygenated xanthones from Leiothrix
Simple pentaoxygenated xanthones
This is a small but growing group as 27 pentaoxygenated xanthones were isolated
between January 2000 and December 2004,5 including drimiopsins A, B and D72 (16, 17
6and 18, respectively) (Figure 7) from Drimiopsis maculata, a South African plant used by
the Zulu to treat digestive disorders in children.
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Figure 7.  Pentaoxygenated xanthones from Drimiopsis maculata
Simple hexaoxygenated xanthones
This subgroup has the highest degree of oxygenation of known naturally
occurring xanthones. Examples include eustomin (19)27,28 and demethyleustomin (20)27-29
(Figure 8) They were extracted from two Centaurium species.
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Figure 8. Hexaoxygenated xanthones from Centaurium
Glycosylated xanthones
This group is further divided into O-glycosides and C-glycosides. The most
common oxygenation is tetraoxygenated, and the families Gentianaceae and
Polygalaceae are the greatest sources of both subgroups.5 An example of a O-glycoside is
umbilicaxanthoside A (21) (Figure 9), which was isolated from the lichen Umbilicaria
7proboscidea that was collected in the Ural Mountains of Russia.73 Mangiferin (22)74 is an
example of a C-glycoside. Rats that had been injected with mangiferin displayed
enhanced object recognition memory.
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Figure 9. O- and C-glycosides
Prenylated xanthones
Examples of common five-carbon units of prenylated xanthones are 3-methylbut-
2-enyl (substituent A), 3-hydroxy-3-methylbutyl (substituent B) and 1,1-dimethylprop-2-
enyl (substituent C) (Figure 10).5 These substituents can cyclize with the ortho hydroxyl
group to form 2,2-dimethylpyrano (as in 23),30 2,2,3-trimethylfuran (as in 24),31 and 2-
isopropenyldihydrofuran (as in 25)25 (Figure 11). The benzofuran and benzopyran
structural motifs generated in this way are privileged structures present in numerous
bioactive natural products.76 Recently, from Psorospermum molluscum harvested from
the Madagascar rain forest, Kingston and co-workers77 isolated psoroxanthin (26) and 8-
(4ʹ′-hydroxyprenyl)-1,7-dihydroxyxanthone (27) (Figure 12). Psoroxanthin showed
promising cytotoxic activities. It is related structurally to psorospermin (28),78 an angular
furoxanthone with a reactive epoxide substituent. Compound 28 was isolated from the
African plant Psorospermum febrifugum, and it possesses biological activity in the 9KB
cell culture and in vivo P388 mouse leukemia systems.
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Figure 10.  Five-Carbon Substituents
O
O
O
OH
23
O
O
OH
OH
24
O O
O
OH
25
OH
OH
O
Figure 11.  Products from the cyclization of five-carbon substituents with a o-hydroxyl
group
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Figure 12.  Xanthones from Psorospermum molluscum (26, 27) and psorospermin (28)
from Psorospermum febrifugum
Xanthonolignoids
This group is relatively small. Kielcorin (29) (Figure 12) is a representative
example. It was isolated from Kielmeyera variabilis.10,32
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Figure 13.  Kielcorin, a xanthonolignoid from Kielmeyera variabilis
Bis-xanthones
An example of a bis-xanthone is jacarelhyperol A (30) (Figure 14), which was
isolated from Hypericum japonicum in 2002 by Ishiguro and coworkers.33
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Figure 14.  Jacarelhyperol A, a bis-xanthone from Hypericum japonicum
Miscellaneous
Xanthones with unusual substituents have been isolated that do not fit in any of
these groups. These are classified as miscellaneous. Examples include two chlorinated
compounds (3134 and 3235) from Dimelaena lichen (Figure 15).
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Figure 15.  Miscellaneous xanthones from Dimelaena lichen
BIOSYNTHESIS OF XANTHONES
Biosynthesis of xanthones has been thoroughly investigated in vivo36 and in vitro
with labeled intermediates.37,38 The studies concluded that two processes are involved:
the acetate polymalonic pathway and the mixed shikimate acetate pathway.
Acetate polymalonic route
Xanthones in fungi and lichens are derived from acetate units.39,40 An example of
the acetate polymalonic mechanism was proposed by Birch for the biosynthesis of
ravelenin (33) from Helminthosporium ravenelii (Scheme 1).40
O
O
33
OH
Me R
O
O
O O OO O O
MeO O O O
O
R
OH
OH
Me
8
Scheme 1.  Biosynthesis of ravenelin by the acetate polymalonic pathway
Mixed shikimate acetate pathway
Xanthones of higher plants are biologically synthesized from shikimate and
acetate.41 Phenylalanine—formed from shikimate—loses two carbon atoms from the side
chain and is oxidized to m-hydroxybenzoic acid (Scheme 2). This condenses with three
acetate units to give the intermediate that cyclizes into a substituted benzophenone. An
oxidative phenol coupling reaction forms the central ring, completing the xanthone.42
Proof of this pathway came from studies on Gentiana lutea by Atkinson43 and Gupta and
Lewis.38 Plants fed 14C-labeled phenylalanine produced xanthones with the label only
observed in ring B, while plants fed 14C-labeled acetate yielded xanthones with the label
only in ring A.
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The intramolecular reaction of benzophenone also occurs by other mechanisms,
including: quinone addition,44 dehydration between hydroxyl groups on ring A and ring B
(2,2´-dihydroxybenzophenone), 45 or formation and then rearrangement of a
spirodienone.41,46
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Scheme 2.  Biosynthesis of xanthones by the mixed shikimate acetate pathway
SYNTHESIS OF XANTHONES
Naturally occurring xanthones contain different types of substituents in different
positions, which leads to a diverse array of structures and pharmacological activities.47
The structures of naturally occurring xanthones are limited by the biosynthetic pathways.
Therefore, a main objective of the synthesis of new derivatives is to develop more diverse
and complex xanthones for biological activity and structure-activity studies.48 Distillation
12
of a mixture of phenol, a o-hydroxybenzoic acid and acetic anhydride was one of the first
methods used for synthesizing xanthones.49,50 Milder conditions have been developed
since then.
Classical Methods
There are three traditional methods for the synthesis of simple xanthones:  the
Grover, Shah, and Shah (GSS) reaction, the synthesis via benzophenone intermediates,
and the synthesis via diphenyl ether intermediates.
Grover, Shah, and Shah reaction
Hydroxyxanthones such as 37 are prepared from accessible starting materials
using the GSS reaction (Scheme 3). It requires derivatives of salicylic acid such as 34 and
an activated phenol such as phloroglucinol (35). These are heated in the presence of
ZnCl2 and POCl3.51 The benzophenone intermediate (36) is not isolated during this one
pot procedure. The procedure has been modified to give better yields by substituting the
phosphorus oxychloride-zinc chloride catalyst with phosphorus pentoxide-
methanesulfonic acid (Eaton’s reagent).52
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Scheme 3.  Grover, Shah, and Shah reaction
13
O
X OHR R
HO
W
X
R R
BENZOPHENONE
R R
O
COOH
DIARYL ETHER
Friedel-Crafts
W = COCl          X = OH
       COOH               OMe
       CN                     H
Ullmann
W = COOH        X = F, Cl, Br, I
        COOMe
O
O
OH R
R
        Fries 
Rearrangement
      Smiles
Rearrangement
DIARYL ESTER
O
O
XANTHONER R
Pyrolysis
a
b
c
d
e
f g
Scheme 4.48  Conventional methods for the synthesis of xanthones
Synthesis via a benzophenone intermediate
The GSS reaction does not always give the required products, and unwanted
demethylations may occur, which led Quillinan and Scheinmann to develop an alternative
method.53 Their efficient general synthesis involves formation of 2-hydroxy-2´-
methoxybenzophenones, followed by the quantitative elimination of methanol in the
presence of alkali to give xanthones (a – b in Scheme 4).48 They used the method to
synthesize benzophenones, and mono- to pentaoxygenated xanthones. The Friedel-Crafts
acylation of 1,2,3,4-tetramethoxybenzene (39) with 2,4,6-trimethoxybenzoyl chloride
(38) in the presence of aluminum chloride in ether gave 2-hydroxy-2´,3,4,4´,5,6´-
hexamethoxybenzophenone (40) (Scheme 5). The structure of 40 was established from
the 1H NMR spectrum:  the two phloroglucinol protons resonated as a singlet. The ortho-
14
monodemethylation occurred selectively at the more electron rich ortho-ether function of
the benzophenone because this group is able to coordinate with the Lewis acid and the
carbonyl group for the demethylation reaction.54 Cyclization of 40 with aqueous alkali
gave the 1,3,5,6,7-pentamethoxyxanthone (41).
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OMe
MeO
OMe
OMeMeO O HO OMe
38 39
40 41
O
Cl
OMe OMe
OMe
OMe
OMe
OMe
OMe
OMe
AlCl3
30 h, rt
NaOH
H2O
Reflux
6 h
Me
+
Scheme 5. Benzophenone intermediate from a Friedel-Crafts acylation
Nishiyama and co-workers used the benzophenone approach in the first direct
synthesis of α-mangostin, a potent inhibitor of the acidic sphingomyelinase.55 Coupling
between the anion of 42 and aldehyde 43 provided benzhydrol 44, which was oxidized
with 2-iodoxybenzoic acid (IBX) and then deprotected to benzophenone 45 (Scheme 6).
The key cyclization reaction was achieved with PPh3-CCl4. The transformation may
begin with phosphorylation of the phenols followed by abstraction of triphenylphosphine
oxide. MOM deprotection occurred simultaneously.
Another way to access the benzophenone intermediate is through the photo-Fries
rearrangement of diaryl esters, (pathway f in Scheme 4). Finnegan and Merkel wanted
2,5-dihydroxyxanthone (49) (Scheme 7).56 Using the GSS reaction conditions with 2,3-
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dimethoxybenzoic acid and 1,4-dimethoxybenzene, they did not get the xanthone since
demethylation was the primary reaction. Therefore, the diaryl ester 47 was transformed
into benzophenone 48 using a photo-Fries rearrangement followed by demethylation with
hydrogen bromide. When heated in a sealed tube with water, 48 underwent
cyclodehydration forming the xanthone.
Br
OBnBnO
OMOM
OBn
42
MeO
BnO
MeO
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2. Pd/C, HCO2NH4
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OHHO
MeO
O
OH OH
1. PPh3, CCl4
2. Silica gel
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OHHO
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Scheme 6.  Synthesis of α-mangostin via benzophenone
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Scheme 7.  Benzophenone from a photo-Fries rearrangement
Larock and Zhou reported the synthesis of benzophenones using a palladium-
catalyzed C—H addition of arenes to nitriles.57 Using simple phenols and 2-
fluorobenzonitrile (50) as starting materials, followed by intramolecular cyclization,
various xanthones were prepared from cheap, readily available starting materials in
moderate yields (Scheme 8). It is proposed that this chemistry involves palladium-
16
catalyzed C—H activation of the simple arene, followed by an unusual carbopalladation
of the nitrile.
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cat. Pd(OAc)2
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R R
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50
FOH
Scheme 8.  Benzophenones from Pd-catalyzed C—H addition of arenes to nitriles
Synthesis via a diphenyl ether intermediate
Diaryl ethers can be synthesized by the Ullmann condensation58 between phenols
or sodium phenolates and o-halogenated benzoic acids, followed by electrophilic
cycloacylation of the 2-aryloxybenzoic acids to prepare xanthones, (pathway c – d in
Scheme 4). A disadvantage of this method is the low yield common to Ullmann
condensations.
2-Carboxy-4´-methoxydiphenyl ether (53) was obtained in a 50% yield when o-
chlorobenzoic acid (51) was condensed with p-methoxyphenol (52) in hot pentyl alcohol,
potassium carbonate, and catalytic copper bronze (Scheme 9).59 When the reaction was
carried out using the original method of Ullmann and Zlokasoff, the yield was 30%.
Cyclization to xanthone 53 occurred in 94% yield when a solution of the ether in acetyl
chloride and concentrated sulphuric acid was heated to distill off acetyl chloride. When
polyphosphoric acid (PPA) was used, cyclization occurred in 84% yield.
Jackson required gram quantities of xanthone 56 (Scheme 10) as part of his effort
to develop potent and specific leukotriene B4 receptor antagonists.60 The Ullmann
coupling between 4-bromo-1,3-benzenedicarboxylic acid dimethyl ester and 3-
methoxyphenol yielded 55 in only 32%. In the cyclization step, phosphorus pentoxide-
17
methanesulfonic acid (Eaton’s reagent) was used instead of PPA because the latter is
difficult to work with in large quantities.
CO2H
Cl MeO
OH K2CO3, Cu
pentyl alcohol
reflux, 5 h, 50%
CO2H OMe
O
+
OMe
O
O
H2SO4
AcCl
94%
51 52
53 54
Scheme 9.  Ullmann ether synthesis followed by cyclization to a xanthone
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         32%
55
Scheme 10.  Eaton’s reagent used to cyclize a diaryl ether to a xanthone
The Smiles rearrangement is another way to access the diaryl ether intermediate
(pathway g in Scheme 4). Elix and co-workers developed this method to synthesize 61
during their study of xanthones from the lichen Rinodina thiomela (Scheme 11).61 Ester
59 was prepared by condensation of acid 57 and phenol 58 in the presence of N,N´-
dicyclohexlcarbodiimide (DCC). Treating 59 with potassium carbonate in anhydrous
dimethyl sulfoxide effected the Smiles rearrangement to carboxylic acid 60 in 63% yield.
This was treated with trifluoroacetic anhydride to give the xanthone.
18
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Scheme 11.  Diaryl ether from a Smiles rearrangement
Improvements have been made in the synthesis of 1,2-dioxygenated xanthones
through direct metalation of diphenyl ether intermediates using lithium diisopropylamide
(LDA).62 Traditional Friedel-Crafts acylation resulted in mixtures in an attempt to
synthesize 1,2-dihydroxyxanthone.48 The anionic cyclization tactic with LDA avoids the
harsh conditions and isomeric mixture separation problems normally observed in the
Friedel-Crafts reaction.62 Sousa synthesized 1,2- and 2,3-dihyroxyxanthone, 63 and 64,
respectively (Scheme 12), from a common intermediate, carboxylic acid 62.63 Directed
metalation with LDA resulted in 63, while electrophilic cyclization with acetyl chloride
resulted in 64.
Intermolecular acylation reactions generally give higher yields than Ullmann
ether syntheses. Therefore, acylation followed by cyclization is the more often used
strategy.48 For example, xanthone 67 (Scheme 13) was obtained in 51% yield from 2-
chloronicotinic acid (65) after treatment with thionylchloride, followed by the acylation
of phloroglucinol in the presence of aluminum trichloride to give ketone 66, followed by
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treatment with aqueous sodium carbonate to effect cyclization.64 An Ullmann
condensation of 65 with phenol 68 gave diaryl ether 69, which was treated with PPA to
effect cyclization and then BBr3 to demethylate to 67 in 41% overall yield.65
O OMe
62
CO2H OMe
O OMe
64
OMe
O
63
OMe
OMeO O
AcCl
H2SO4
LDA
Scheme 12.  1,2-Dioxygenated xanthones from anionic cyclization vs. 2,3-dioxygenated
xanthones from acidic conditions
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CO2HCu, K2CO3
+ 1. PPA2. BBr3
65
Na2CO3
68
N
CO2H
Cl
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Scheme 13. Friedel-Crafts route, 51% over three steps. Ullmann condensation route, 41%
New Methods
Although the classical methods towards xanthones continue to be used to
synthesize newly discovered compounds, new methods have been developed. Aims of the
new methods include constructing densely oxygenated xanthones in a regioselective
manner, reducing the number of steps, making the conditions more mild, and eliminating
toxic reagents.
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Hauser’s Method
Hauser used the sulfone annelation strategy in a regiospecific preparation of the
benz[b]xanthen-12-one ring system.66 Condensation of the anion of phthalide 71 with
chromone 70 gave 72 in 27% yield (Scheme 14).
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MeO
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O OMe
OMe
OMePhO2S
O
OMe
MeO
OH
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OMe
OMe
OMe
LiO-t-Bu+
70 71 72
Scheme 14.  Regiospecific preparation of the benz[b]xanthen-12-one ring system
Liebeskind Method
Liebeskind’s method67 used dithiane-protected γ-benzopyrone-fused
cyclobutenediones 75 (Scheme 15) to regioselectively synthesize a variety of highly-
substituted xanthones (78) and xanthones fused to aromatic and heteroaromatic rings
(77). These were readily accessed on a large scale from dialkyl squarates and the dianions
of 2-(o-hydroxyphenyl)-1,3-dithianes (73). The 1,2-adducts (74) were treated with p-
toluenesulfonic acid monohydrate (pTSA), which resulted in cyclization to 75.
Nucleophilic addition of different alkenyl, aryl, and heteroaryl anions to 75 occurred at
the less sterically hindered ketone. The 1,2-adducts were quenched with acetic anhydride.
Some of the O-acylated adducts (76) derived from aromatic anions could be purified and
characterized, but it was more efficient to warm the crude adducts to room temperature
and then isolate the benzannulated products. Treatment with HgCl2 completed the
synthesis of xanthones.
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Scheme 15.  Benzannulation with cyclobutenediones
Larock’s One Step Methods
Most syntheses of the xanthone skeleton involve multiple steps, harsh reaction
conditions, strong acids, and/or toxic metals. Using Kobayashi’s68 mild approach to
arynes from silylaryl triflates, Larock and Zhao69 developed a general, one-pot approach
to xanthones, thioxanthones and derivatives. The reaction of o-(trimethysilyl)aryl triflates
(80, Scheme 16), salicylates (79) and CsF afforded xanthones and thioxanthones through
a mechanism that proceeds by a tandem intermolecular nucleophilic coupling, followed
by intramolecular electrophilic cyclization.
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80
Scheme 16:  One-pot synthesis of xanthones and thioxanthones
            Larock and Dubrovskiy70 in 2010 developed a second one-step route to xanthones.
This procedure uses o-(trimethylsilyl)aryl triflates and CsF to generate an aryne, which
inserts into the C—O bond of readily available o-halobenzoic acids. After subsequent
rearrangements, nucleophilic aromatic substitution with a phenolate formed in situ results
in cyclization of the pyrone. The reaction between o-fluorobenzoic acid (81) and 3-
methoxybenzyne precursor 3-methoxy-2-(trimethylsilyl)phenyl triflate (82) with CsF
provided 1-methoxyxanthone (83) in 71% yield (Scheme 17). Only one regioisomer was
formed since the reaction is controlled electronically.70
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OTf O
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Scheme 17.  Intermolecular C—O addition of a carboxylic acid leading to a xanthone
Inverse electron demand Diels-Alder approach
Bodwell and co-workers75 synthesized a series 2 substitued 4-methoxyxanthones
(86, Scheme 18) and 3,4-dimethoxyxanthones (88) using a cascade of reactions initiated
by an inverse-electron-demand Diels-Alder reaction (IEDDA). The dienes were electron-
deficient chromones (84) and the dieneophiles were either 1-(2,2-
dimethoxyvinyl)pyrrolidine (85) or tetramethoxyethene (87). For experiments employing
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87, the series of reactions—IEDDA/elimination (MeOH)/elimination (MeOH)—was
interrupted after the first elimination, which led to unaromatized byproducts. Treatment
with Et2O⋅BF3 converted the byproducts to xanthones.
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Scheme 18.  Inverse-electron-demand Diels-Alder approach
KRAUS APPROACH TO XANTHONES
The use of herbal medicines is increasing.79 The Food and Drug Administration
(FDA) does not regulate herbal medicines since they are classified as dietary
supplements. The second most sold herbal medicine in the United States is St. John’s
Wort—Hypericum perforatum—which is used as an anti-anxiety drug, as an antiviral and
as a topical wound-healing agent. The commercial preparation is a mixture of at least ten
compounds, including hypericin and hyperforin, which are well know and thought to be
the active antidepressant ingredients.80 However, it is necessary to understand the
biological activities of all the major components to avoid unfavorable drug interactions.
As mentioned above (Figure 4), the 1,7-dioxygenated xanthones euxanthone (9) and 1-
methoxy-7-hydroxyxanthone (10) are found in St. John’s Wort.
Euxanthone shows potential as a pharmaceutical because of its biological
activities: it promotes neurite outgrowth by selectively activating the MAP kinase
pathway,81 it showed inhibitory effects on the growth of Plasmodium falciparum with
IC50 values in the milligram/milliliter level,82 and it inhibited HIV-1 reverse transcriptase
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with IC50 values at the milligram/milliliter level.83 In a vasodilation assay, both xanthones
9 and 10 exhibited relaxing activity on the contractions evoked by potassium chloride in
rat thoracic aorta rings in a dose-dependent manner.84 Patel and Trivedi synthesized
euxanthone by heating hydroquinone and ethyl 2,6-dihydroxybenzoate in boiling
diphenyl ether.85 The transformation proceeds through a diaryl ester intermediate, which
rearranges to the xanthone by pyrolysis (pathway e in Scheme 4). Our synthetic route to 9
requires three steps from two commercially available starting materials and is amendable
to scale up.
After establishing our route to simple 1,7-dioxygenated xanthones, we made
progress towards the synthesis the prenylated 1,7-dioxygenated xanthones from
Psorospermum molluscum (26, 27, Figure 12). During isolation, Kingston used the
Escherichia coli SOS PQ37 chromotest assay—a DNA reactivity assay—to guide the
fractionation of the plant extract.77 Compound 26 displayed highly potent SOS activity. It
is likely that 26 is a biogenetically derived oxidation product of 27.77 The isolated
quantities of 26 were too small to determine the stereochemistry, so synthesis is required.
RESULTS AND DISCUSSION
The key step of our synthetic route to the simple 1,7-dioxygenated xanthone core
was the photoacylation86 of benzoquinone with 2,6-dimethoxybenzaldehyde (Scheme 19).
The Kraus lab developed the photoacylation of quinones as a benign alternative to certain
Friedel-Crafts reactions. Advantages of this reaction include atom economy, readily
available and stable starting materials, and generality concerning the aldehyde
component. Adducts from the reaction have been used in syntheses of benzodiazepines
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and natural products such as frenolicin.86c Concerning benign chemistry, a disadvantage
of the procedure is the use of hydrocarbon solvents such as benzene and acetonitrile.
However, supercritical carbon dioxide (SC-CO2) has been reported as an alternative
solvent and was used in the benzophenone-mediated photoacylation of 1,4-benzoquinone
with benzaldehyde or butyraldehyde.86e In a large-scale application of the photoacylation,
Mattay and co-workers used a t-butanol-acetone mixture (3:1, 80 L) as the solvent for the
acylation of 1,4-napthoquinone (500 g) with butyraldehyde (4 kg).87 Before we
synthesized 89, a hindered aldehyde had not been used because the reaction generates an
acyl radical, which could undergo an intramolecular 1,5-hydrogen atom transfer prior to
coupling with the quinone.88
H
O
O
O
O OH
OH
OMe
OMe
OMe
OMe
Light
2 eq. Ph2CO
Ph-H, rt, 7 days
OH
O
O
OMe
OMe
+ +
89 90
Scheme 19.  Photoacylation reaction with benzoquinone
The benzophenone-mediated reaction generated the desired adduct 89 and a
byproduct, monoester 90. The two adducts and unreacted 2,6-dimethoxybenzaldehyde
were inseparable by column chromatography, so acid-base extraction was used to
separate the phenolic products from the recovered aldehyde and benzophenone.
Possible pathways (Scheme 20) leading to 89 and 90 begin with hydrogen atom
abstraction86b, 89 from the formyl group of 2,6-dimethoxybenzaldehyde by the triplet
excited state of benzophenone to generate the acyl radical A. In Path 1, A then adds 1,4 to
the quinone, resulting in stabilized semiquinone radicals B and Bʹ′. Finally, the
benzhydrol radical donates a hydrogen atom to regenerate benzophenone and produce
hydroquinone 89. In Path 290, a single electron transfer between A and benzoquinone
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gives the acylium ion C and a radical anion, which couple to form stabilized radicals D
and Dʹ′. In the last step, hydrogen abstraction produces 90.
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Scheme 20.  Mechanisms leading to 89 and 90
We synthesized 91 in 76% yield from naphthoquinone to show the scope of this
reaction (Scheme 21). Monoester formation was not observed. Adduct 91 was
demethylated with boron tribromide to give 92, which was cyclized to xanthone 93 in
95% yield with heating at 180 °C for 16 hours.
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Scheme 21.  Synthesis of 5,8-dihydroxy-7H-benzo[c]xanthen-7-one (93)
To synthesize xanthone 10, we treated adduct 89 (along with monoester 90) with
potassium hydroxide in methanol at 100°C for 12 hours to afford compound 10 in 47%
yield over two steps.91 Demethylation of 10 with boron tribromide afforded euxanthone
(9) in 75% yield.
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Scheme 22.  Synthesis of 1-methoxy-7-hydroxyxanthone and euxanthone
Our synthetic effort towards 27 is outlined in Scheme 23. The key step in this
series was the selective ortho-Claisen rearrangement to place the allyl group at the
position ortho to the carbonyl, intermediate 96. The rearrangement of allylphenyl ethers
to o-allylphenols forms a mixture of isomers when the system is unsymmetrical.93
However, certain m-acyl groups do have a directing effect. Ketones such as 99 rearrange
exclusively to 100 (Scheme 24).94 Kraus and Fulton synthesized polycyclic systems by
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coupling the rearrangement with an intramolecular Diels-Alder reaction using ketone
101. Aromatization of the central ring with 2,3-dichloro-5,6-dicyanobenzoquinone
(DDQ) afforded naphthoquinone 103.
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Scheme 23.  Synthesis of hydroxyprenylated xanthone 27
R
OOH
O
R
O
OH
OH
∆
99 100
OOH
O
OH
OH
∆
101 102
OH O OH O
O
103
OH O
2 DDQ
Scheme 24.  Regioselective ortho-Claisen rearrangements
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Allylation of 10 afforded xanthone 94 in 80% yield. To determine whether or not
an ortho-hydroxy group is necessary to effect selectivity in rearrangement, we heated the
O-methyl xanthone (94) at 200 ºC in a sealed tube with toluene. This resulted in a
complex mixture. Therefore, we selectively removed the O-methyl group using boron
tribromide in methylene chloride to afford a 67% yield of 95. However, the reaction was
not clean. In addition to recovered starting material, di-dealkylation gave euxanthone as a
byproduct. Euxanthone could be selectively allylated at the 7-postion to give 95 in 57%
yield. The ortho-Claisen rearrangement cleanly gave dihydroxyxanthone 96 in 69% yield,
when the allyl ether was heated at 220-230 ºC for three hours in a sealed tube with
mesitylene. Acetylation of the hydroxy groups using acetic anhydride, 4-
dimethylaminopyridine (DMAP) and triethyl amine gave diacetate 97 in 94% yield. Next,
ozonolysis and in situ Wittig reaction95 with the stabilized ylide ethyl 2-
(triphenylphosphoranylidene)propanoate96 furnished a mixture of E and Z α,β-
unsaturated esters 98 in 43% yield. The major product was the E isomer since stabilized
ylides furnish high E selectivity.97 We did not isolate the aldehyde and we used mild
conditions to effect the Wittig reaction since the aldehyde’s stability was a concern owing
to the mutually benzylic and α-hydrogen atoms. When we made progress towards 26, the
aldehyde was isolated.
It should be noted that before employing the oxidation/in situ Wittig
reaction protocol, we attempted a ruthenium catalyzed cross metathesis (CM). Grubbs
has successfully coupled allyl benzene (104) and 1,4-diacetoxy-2-butene (105) (Scheme
25).98 The two components behave similarly in the CM reaction, so 2 equiv of 105
(corresponding to 4 equiv of allylacetate) were used to increase the statistical yield of the
heterocoupled product 106. The reaction produced a six-component mixture of E/Z
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heterocoupled 106, E/Z 1,4-diacetoxy-2-butene, and E/Z homocoupled allylbenzene. The
first and second-generation catalysts were compared. The second-generation was more
active than the first-generation since the former had faster reaction times and higher total
conversions. However, the E/Z ratio for the first-generation was ~5 throughout the course
of the reaction, while the E/Z ratio for the second-generation was ~3 early in the reaction
then rising to ~10 as the conversion increased. With this information, we used the first-
generation catalyst to couple allylxanthone 97 with 2-methylallylacetate (107).
Unfortunately, the reaction returned the xanthone starting material and produced E/Z
homocoupled 107. The same result was reached with the second-generation catalyst.
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Scheme 25.  CM reactions between allyl benzenes and allyl acetates
Although the E,Z-selectivity of the Wittig reaction was not in our favor, we
fortunately did have a small percentage of the Z-olefin ready for reduction to the natural
product 27. Using diisobutylaluminium hydride (i-Bu2AlH), several attempts all resulted
in complex mixtures. Considering an alternate pathway the reaction could take (Scheme
25), if the phenoxide formed ortho to the unsaturated ester (109), conjugate addition
could result, leading to the benzofuran 110.
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Scheme 25.  A possible side reaction during the reduction step
To investigate the cyclization reaction, 98 was treated with sodium methoxide
(Scheme 26). Methanolysis, Michael addition and transesterification occurred to afford
one compound (111) in 97% yield.
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Scheme 26.  Treatment of 98 with NaOMe affords a benzofuran
The ease of cyclization coupled with the difficulty in preparing the Z-olefin
encouraged us to make a synthetic attempt toward the furanoxanthone 26, psoroxanthin.
As mentioned above, it is structurally related to psorospermin (28), which Kupchan first
isolated in 1980.78 In 1987, Cassady assigned the absolute stereochemistry99 as 2´R,3´R,
and he confirmed the assigned configuration with the total synthesis100 of the O5-methyl-
(±)-2´R,3´S epimer. Schwaebe completed the first total synthesis101 of psorospermin in
2005.
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Scheme 27 shows Cassady’s synthesis100 of O5-methyl-(±)-2´R,3´S-psorospermin
beginning with a key intermediate, aldehyde 112. The Wittig reaction of it with
(carbethoxyethylidene)triphenylphosphorane gave the ester (E)-113 in 47% yield. That
assignment was based on 1H NMR chemical shift correlation. The vinyl proton resonated
at δ 6.87 (6.60 calcd for E isomer, and 6.03 for Z). Diisobutylaluminum hydride did not
effect the reduction, so lithium aluminum hydride was used to afford allylic alcohol 114
in 50% yield. Epoxidation with m-chloroperbenzoic acid (mCPBA) produced racemic
epoxides in 70% yield. The allylic alcohol was mesylated and then the benzyl phenol was
deprotected to give 115. Treatment with potassium tert-butoxide in tert-butyl alcohol
produced the phenoxide ion (115a) that opened up the epoxide in an SN2 reaction, which
formed the furan ring as the alkoxide ion left. That anion (115b) participated in a second
SN2 reaction, which formed the epoxide as the mesylate left. The stereochemical outcome
of Cassady’s zipper-type reaction was set by the stereochemistry of ester 113 and the
racemic mixture of epoxides.
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Scheme 27.  Cassady’s zipper-type reaction
In Schwaebe’s total synthesis of psorospermin,101 he set the (2´R,3´R)-
stereochemistry of the natural product by selectively forming the Z-olefin, 119 (Scheme
28), using the Z Horner—Emmons method developed by Still and Gennari.102 Schwaebe
also was able to differentiate the 1- and 5-hydroxys, which allowed for the selective
protections and deprotections necessary to complete the synthesis. Aldehyde 117 was
added to a solution of trifluoroethylphosphonoester 118 and KN(SiMe3)2/18-crown-6,
which resulted in a 10:1 ratio of the Z/E unsaturated ester. Crystallization afforded pure Z
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olefin 119 in 76% yield. Reduction with i-Bu2AlH gave the allylic alcohol in 42% yield.
Sharpless epoxidation103 produced 120 in 78% yield with a 70% ee.
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Scheme 28.  Steps establishing the stereochemistry in Schwaebe’s total synthesis of
psorospermin
FUTURE WORK
We could selectively synthesize derivatives of 26 with Schwaebe’s method using
the E and the Z-olefins with (–) DIPT and (+) DIPT. Scheme 29 outlines the synthesis of
2´R,3´R derivative, 26a. Instead of using aldehyde 121 (Figure 16), which was isolated
and stable, the dibenzyl aldehyde 122 would be used to avoid cyclization during the
reduction step.
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Scheme 29.  A planned synthesis of 2´R,3´R derivative, 26a
CONCLUSION
Two bioactive components from Hypericum perforatum have been synthesized by
direct routes. These results further extend the synthetic utility of the photoacylation of
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quinones. Progress was made toward the first total synthesis of psoroxanthin using a
regioselective ortho-Claisen rearrangement.
EXPERIMENTAL
Unless otherwise noted, materials were obtained from commercial suppliers and
used without purification. Tetrahydrofuran and diethyl ether were distilled from sodium
and benzophenone. Dichloromethane, benzene and diisopropyl amine were distilled over
calcium hydride. All experiments were performed under an argon atmosphere unless
otherwise noted. Organic extracts were dried over anhydrous magnesium sulfate. Nuclear
magnetic resonance experiments were performed with either a Varian 300 MHz or Varian
400 MHz instrument. All chemical shifts are reported relative to CDCl3 (7.27 ppm for 1H
and 77.23 ppm for 13C), unless otherwise noted. Coupling constants (J) are reported in Hz
with abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. High
resolution mass spectra were recorded on a Kratos model MS-50 spectrometer. Standard
grade silica gel (60 Å, 32-63 µm) was used for flash column chromatography.
OOMe
O
OH
1-Methoxy-7-hydroxyxanthone (10): A 2.5 cm x 20 cm Pyrex test tube was charged with
2,6-dimethoxybenzaldehyde (544.6 mg, 3.24 mmol), benzoquinone (354 mg, 3.27
mmol), and benzophenone (1.32 g, 7.22 mmol). The tube was equipped with a stir bar,
charged with dry benzene (45 mL) and sealed. The solution was degassed with argon (15
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min) and irradiated in a Rayonet photochemical reactor (7 days). Crystals precipitated out
of the reaction mixture. The mixture was poured into a 250 mL round bottom flask, the
tube was rinsed with acetone and the solvents were removed by distillation on a rotary
evaporator. Five percent NaOH (20 mL) was poured into the flask and then the aqueous
solution was poured into a separatory funnel and extracted with ether (3x 20 mL). The
aqueous layer was cooled to 0 °C, acidified with concentrated HCl and then extracted
with ether (3x 20 mL). The organic layer was concentrated in vacuo to reveal a dark
yellowish-brown tar (850.4 mg), which was a mixture of 89 and the monoester (90). The
mixture was transferred to a pressure tube with MeOH (30 mL). The tube was equipped
with a stir bar, charged with KOH (1.74 g, 31 mmol), sealed at 0°C, and heated at 110°C
(24 h). The solution was poured into ice, acidified with concentrated HCl and extracted
with EtOAc (3x 20 mL). The organic layer was dried over MgSO4 then concentrated.
Purification by column chromatography (EtOAc:hexanes, 1:4  2:3) removed methyl-
2,6-dimethoxybenzoate and hydroquinone. 10 was eluted with 1:1  9:1 EtOAc:hexanes
as a beige solid (371.7 mg, 1.53 mmol) in 47% over two steps, which crystallized from
MeOH as yellow needles, m.p. 238-240 °C (lit.104 238-240 °C). All spectra were identical
with those previously reported.104
O OH
OH
OMe
OMe
(2,5-Dihydroxyphenyl)(2,6-dimethoxyphenyl)methanone (89): 1H- NMR (acetone-d6) δ
11.71 (s, 1H), 7.46 (t, J = 8.00 Hz, 1H), 7.09 (dd, J = 8.00 Hz, J = 4.00 Hz, 1H), 6.87 (d,
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J = 8.00 Hz, 1H), 6.80 (d, J = 8.00 Hz, 2H), 6.70 (d, J = 4.00 Hz, 1H), 3.73 (s, 6H);
HRMS (EI) m/z calcd. for C15H14O5 274.0841, found 274.0846.
OOH
O
OH
Euxanthone (9): To a stirred suspension of 10 (152.1 mg, 0.628 mmol) in CH2Cl2 (30 mL)
at –78 °C was added 1.0 M BBr3 solution in CH2Cl2 (0.942 mL, 0.942 mmol). The
reaction mixture was slowly allowed to warm to rt, stirred overnight, cooled to 0 °C,
quenched with water, and extracted with CH2Cl2. The combined organic layers were
washed with water, dried (brine, MgSO4), filtered, concentrated in vacuo, and purified by
column chromatography (15% EtOAc in hexanes) to afford 1 as yellow needles (107.1
mg, 0.469 mmol, 75% yield) m.p. 236-238 °C (lit.105 236-238 °C).
OOH
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(1,4-Dihydroxynaphthalen-2-yl)(2,6-dimethoxyphenyl)-methanone (91): A 2.5 cm x 20
cm Pyrex test tube was charged with naphthoquinone (98 mg, 0.62 mmol), 2,6-
dimethoxybenzaldehyde (95 mg, 0.565 mmol) and benzophenone (31 mg, 0.17 mmol).
Dry benzene (19 mL) was added then the solution was degassed with argon (15 min). It
was irradiated in a Rayonet photochemical reactor (5 days). Crystals precipitated out of
the reaction mixture. The solution was concentrated in vacuo and the residue was purified
by column chromatography (hexanes-EtOAc 19:11:3) to afford 139 mg (76%) of 91 as
bright yellow needles, m.p. 194-196 °C; 1H-NMR (CDCl3): δ 13.31 (s, 1H), 8.52 (d, J =
8.00 Hz, 1H), 8.08 (d, J = 8.00 Hz, 1H), 7.68 (t, J = 8.00 Hz, 1H), 7.59 (t, J = 8.00 Hz,
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1H), 7.38 (t, J = 8.00 Hz, 1H), 6.64 (d, J = 8.00 Hz, 2H), 6.54 (s, 1H), 4.84 (s, 1H), 3.74
(s, 6H); 13C-NMR (CDCl3): δ 200.4, 157.8, 157.4, 143.0, 131.4, 129.9, 129.8, 126.1,
124.8, 121.8, 116.8, 113.9, 107.7, 104.2, 56.2; HRMS (EI) m/z calcd. for C19H16O5
324.0998, found 324.0998.
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5,8-Dihydroxy-7H-benzo[c]xanthen-7-one (92): An oven-dried 50-mL round bottom
flask equipped with a stir bar was charged with benzophenone 91 (27.3 mg, 0.0842
mmol) and CH2Cl2 (3.0 mL). Then BBr3 (337 µL, 1.0 M in CH2Cl2, 0.337 mmol) was
added in drops over 1 min. The deep red solution was stirred at rt for 8 h and then cooled
to 0 °C before quenching with 2 mL H2O. The mixture was warmed to rt, diluted with
CH2Cl2 (20 mL), poured into a separatory funnel and then the organic layer was washed
with H2O (2x 20 mL), brine (1x 20 mL), dried over MgSO4, filtered and concentrated in
vacuo to afford an orange solid that was purified by column chromatography
(hexanes:EtOAc; 3:2) to afford the tetrahydroxybenzophenone as an orange solid (16 mg,
0.0540 mmol, 64%); 1H-NMR (acetone-d6): δ 8.67 (s, 1H, exchangeable with D2O), 8.57
(s, 1H, exchangeable with D2O), 8.44 (d, J = 8.0 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.71
(t, J = 8.0 Hz, 1 H), 7.62 (t, J = 8.0 Hz, 1 H), 7.18 (t, J = 8.0 Hz, 1 H), 6.78 (s, 1 H), 6.55
(d, J = 8.0 Hz, 2 H); 13C-NMR (acetone-d6): δ 202.3, 156.3, 145.5, 132.0, 130.9, 130.2,
127.1, 126.7 (overlap of two C), 124.8, 123.1, 115.9, 115.4, 108.1, 107.9.
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5,8-Dihydroxy-7H-benzo[c]xanthen-7-one (93): A pressure tube was equipped with a stir
bar and charged with the 5,8-Dihydroxy-7H-benzo[c]xanthen-7-one (18.9 mg, 0.0638
mmol), H2O (1.6 mL) and DMF (1.0 mL). The resulting solution was sealed at 0 °C and
then heated for 16 h at 180 °C. A yellow solid precipitated. The mixture was cooled to 0
°C before opening and diluting with EtOAc (10 mL). The mixture was poured into a
separatory funnel. The organic layer was washed with H2O (2x 10 mL) and brine (1x 10
mL), dried over MgSO4, filtered and concentrated in vacuo to afford a yellow solid that
was purified by column chromatography (hexanes:EtOAc; 9:1) to afford the xanthone 93
as a yellow solid (17 mg, 0.064 mmol, 95% yield); 1H-NMR (DMSO-d6): δ 12.72 (s, 1 H,
exchangeable with D2O), 8.60 (d, J = 8.0 Hz, 1 H), 8.27 (d, J = 8.0 Hz, IH), 7.81 (dt, J =
8.0 Hz, 2H), 7.73 (t, J = 8.0 Hz, IH), 7.34 (s, 1 H), 7.26 (d, J = 8.0 Hz, IH) 6.82 (d, J =
8.0 Hz, IH); 13C-NMR (DMSO-d6) δ 181.5, 161.0, 155.8, 150.5, 147.8, 137.0, 130.2,
129.5, 128.4, 124.6, 123.3, 123.1, 116.8, 110.4, 109.0, 107.9, 98.8.
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7-(Allyloxy)-1-methoxy-9H-xanthen-9-one (94): In a 100 mL round bottom flask fitted
with a stir bar, 1-methoxy-7-hydroxyxanthone (390.1 mg, 1.610 mmol) was taken up in
dry acetone (30 mL). Anhydrous K2CO3 (447.2 mg, 3.22 mmol) was added to the
solution at 0 °C. To the suspension was added allyl bromide (292.8 mg, 205 µL, 2.42
mmol) in acetone (1 mL) over 1 min. The flask was fitted with a heat exchanger and
boiled overnight. The mixture was cooled to rt then filtered though Celite and rinsed with
acetone. The filtrate was concentrated in vacuo then purified by column chromatography
(EtOAc:hexanes, 1:1) as a yellowish solid (362 mg, 1.28 mmol, 80 %). 1H-NMR
(acetone-d6) δ 7.67 (t, J = 8.0 Hz, 1H), 7.59 (d, J = 3 Hz), 7.44 (d, J = 8.0 Hz), 7.36 (dd, J
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= 8.0 Hz, 3.0 Hz), 7.05 (d, J = 8.0 Hz), 6.93 (d, J = 8.0 Hz), 6.16-6.07 (m, 1H), 5.47 (d, J
= 16 Hz, 1H) 5.29 (d, J = 12 Hz, 1H) 4.68 (d, J = 4 Hz, 2H), 3.95 (s, 3H). 13C-NMR
(CDCl3) δ 176.1, 160.5, 157.9, 154.7, 149.6, 134.5, 132.6, 124.2, 123.1, 118.5, 118.0,
111.9, 109.8, 107.3, 105.0, 69.2, 56.3.
OOH
O
O
7-(Allyloxy)-1-hydroxy-9H-xanthene-9-one (95): Dissolved 94 (367 mg, 1.30 mmol) in
dry CH2Cl2 (30 mL), stirred and cooled to –15 °C. Added BBr3 (0.650 mmol, 0.650 mL
of 1.0 M solution in CH2Cl2) dropwise. Slowly allowed the solution to warm to rt
overnight. TLC showed a mixture of the desired product, euxanthone and starting
material. The reaction mixture was cooled to 0 °C, quenched with sat. aq. NH4Cl, then
extracted with CH2Cl2. The organic layer was dried over MgSO4, filtered and
concentrated in vacuo. The product was isolated by column chromatography on silica gel:
5% EtOAc in hexanes eluted the product, 15% eluted euxanthone and 30-75% eluted
starting material. The product (232 mg, 0.865 mmol, 67%) was a yellow solid.1H-NMR
(300 MHz, CDCl3) δ 12.67 (s, 1H) 7.63 d, J = 2.8 Hz, 1H), 7.59 (t, J = 8.4 Hz, 1H) 7.44-
7.37 (m, 2H), 6.93 (d, J = 8.4 Hz), 6.79 (d, J = 8.4 Hz, 1H), 6.11-6.05 (m, 1H), 5.48 (d, J
= 18.4 Hz, 1H), 5.36 (d, J = 10.8 Hz, 1H), 4.65 (d, J = 5.2 Hz, 2H); HRMS (EI) m/z
calcd. for C16H12O4 268.0736, found 268.0743.
OOH
O
OH
OOH
O
OAllyl-Br
K2CO3
Acetone
7-(Allyloxy)-1-methoxy-9H-xanthen-9-one (95) from euxanthone (10): In a 100 mL round
bottom flash fitted with a stir bar, euxanthone (107.1 mg, 0.469 mmol) was taken up in
dry acetone (15 mL). Anhydrous K2CO3 (130 mg, 0.936 mmol) was added to the slurry at
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0 °C. To the solution was added allyl bromide (63 mg, 44 µL, 0.521 mmol) dropwise
over 1 min. The flask was fitted with a heat exchanger and boiled overnight. The mixture
was cooled to rt then filtered though and rinsed with acetone. The filtrate was
concentrated in vacuo then purified by column chromatography (5% ethyl acetate in
hexanes) as a yellowish solid (71.4 mg, 0.266 mmol, 57 % yield).
OOH
O
OH
1-Allyl-2,8-dihydroxy-9H-xanthen-9-one (96): A pressure tube was charged with 95
(232.2 mg, 0.8226 mmol) and mesitylene (10 mL), equipped with a stir bar, cooled to 0
°C, sealed, and then heated at 220-230 °C for 3 h. After cooling to rt, the tube was
opened and the reaction mixture was deposited on a column of silica gel in hexanes. The
column was flushed with hexanes to remove mesitylene and then eluted with ethyl
acetate in hexanes. 5% eluted starting material and 10% to 20% eluted the product (160
mg, 69%), a yellow solid. 1H-NMR (CDCl3, 400 MHz) δ 7.55 (t, J = 8.4 Hz, 1H), 7.34-
7.53 (m, 2H), 6.86 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 6.20-6.10 (m, 1H), 5.17-
5.11 (m, 2H), 4.30 (d, J = 6 Hz, 2H). 13C-NMR (acetone-d6, 100 MHz) δ 184.8, 162.2,
155.9, 151.8, 151.7, 137.0, 136.8, 126.3, 124.2, 118.9, 116.9, 114.3, 109.8, 109.1, 106.4,
31.1; HRMS (EI) m/z calcd. for C16H12O4 268.0736, found 268.0737.
OOAc
O
OAc
8-Allyl-9-oxo-9H-xanthene-1,7-diyl diacetate (97): Dissolved the diol (159.7 mg, 0.5953
mmol) and DMAP (7.3 mg, 0.06 mmol) in dry THF (15 mL) at rt with stirring. Added
Ac2O (0.169 mL, 1.79 mmol) followed by dry Et3N (0.249 mL, 1.79 mmol). After 3 h,
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quenched with sat. aq. NH4Cl then extracted with ether. Dried the organic layer over
MgSO4 and concentrated in vacuo to reveal a white solid (198 mg, 0.562 mmol, 94%),
which was used without further purification. 1H-NMR (acetone-d6, 400 MHz) δ 7.63 (t, J
= 8 Hz, 1H), 7.58 (d, J = 8 Hz, 1H), 7.53-7.48 (m, 2H), 7.08 (d, J = 8 Hz, 1H), 5.08 (d, J
= 17 Hz, 1H), 4.94 (d, J = 12 Hz, 1H), 4.01 (d, J = 8 Hz, 2H)), 2.38 (s, 3H) 2.35 (s, 3H).
OOAc
O
OAc
CO2Et
8-(4-Ethoxy-3-methyl-4-oxobut-2-en-1-yl)-9-oxo-9H-xanthene-1,7-diyl diacetate (98). In
a 100 mL round bottom flask fitted with a stir bar, the allyl diacetate 97 (136.6 mg, 0.388
mmol) was dissolved in dry CH2Cl2 (10 mL). The flask was plugged with cotton and
cooled to –78 °C. Ozone was bubbled through the solution until the blue color persisted
(10 min). The solution was then purged with Ar (20 min) followed by addition of solid
PPh3 (152.5 mg, 0.5816 mmol). The mixture was stirred at –78 °C for 1.5 h and then the
ice bath was removed. After warming to room temperature, the stabilized Wittig salt (633
mg, 1.94 mmol) was added in CH2Cl2 (5 mL). The reaction mixture was stirred at rt
overnight then concentrated in vacuo to reveal a rose-colored residue, which was purified
by column chromatography: 5% ethyl acetate in hexanes followed by 50% to afford the
title compound (72.6 mg, 0.616 mmol, 43% yield). 1H-NMR (CDCl3, 300 MHz) δ 7.66 (t,
J = 8.4 Hz, 1H) 7.40-7.34 (m, 3H), 6.97 (d, J = 6.9 Hz, 1H), 6.68 (t, J = 6.3 Hz, 1H),
4.18-4.11 (m, 4H, overlap of ArCH2- and –OCH2CH3), 2.44 (s, 3H), 2.35 (s, 3H), 2.06 (s,
3H), 1.24 (t, J = 7.2 MHz)
44
OOH
O
O
O
OMe
Methyl 2-(10-hydroxy-11-oxo-2,11-dihydro-1H-furo[3,2-a]xanthen-2-yl)propanoate
(111). In a 25 mL round bottom flask, 98 (14.5 mg, 3.31 x 10-2 mmol) was dissolved in
dry MeOH (5 mL). The solution was cooled to 0 °C and then a solution of 1.04 M
NaOMe in MeOH (67 µL, 7.0 x 10-2 mmol) was added dropwise. The reaction mixture
was slowly warmed to rt and then quenched with 1 N HCl. After extraction with ether,
the organic layer was washed with water, dried (brine, MgSO4) and concentrated in
vacuo. Column chromatography with 5-10% ethyl acetate in hexanes afforded the
product (11 mg, 3.23 x 10-2 mmol, 97%). 1H-NMR (CDCl3, 400 MHz) δ 7.56 (t, J = 8 Hz,
1H), 7.27 (d, J = 8 Hz, 1H), 7.18 (d, J = 8 Hz, 1H), 6.89 (d, J = 8 Hz, 1H), 6.75 (d, J = 8
Hz, 1H), 5.21-5.12 (m, 1H), 4.00-3.91 (m, 1H), 3.74 (s, 3H), 3.65-3.55 (m, 1H), 2.87-
2.79 (m, 1H), 1.34 (d, J = 7 Hz).
OOAc
O
OAc
O
9-Oxo-8-(2-oxoethyl)-9H-xanthene-1,7-diyl diacetate (121): A 100-mL round bottom
flask was charged with 97 (62.6 mg, 0.1777 mmol) and CH2Cl2 (10 mL), fitted with a stir
bar and plugged with cotton. While cooling to –78 ºC, first ozone was bubbled through
the solution for 20 min and then Ar was bubbled through for 20 min. Then solid triphenyl
phosphine (70 mg, 0.267 mmol) was added all at once and stirring continued for 1 h
before the ice bath was removed and the solution was allowed to warm spontaneously to
rt. The reaction mixture was then concentrated in vacuo and purified on a column of
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SiO2, first with five percent ethyl acetate in hexane followed by 1:1 to afford the title
compound (25.7 mg, 0.0725 mmol, 41% yield); 1H-NMR (CDCl3, 300 MHz) δ 7.69 (t, J
= 8.5 Hz), 7.51-7.44 (m, 2H), 7.39 (dd, J = 8.9 Hz, 1.1 Hz, 1H), 6.99 (dd, J = 7.83 Hz, 1.1
Hz, 1H), 4.22 (s, 2H), 2.44 (s, 3H) 2.35 (s, 3H). 13C-NMR (CDCl3, 75 MHz) δ 197.6,
177.2, 169.7, 169.1, 156.5, 154.3, 150.1, 145.8, 134.7, 129.2, 126.9, 120.7, 118.4, 118.3,
115.8, 115.1, 41.5, 21.2, 20.8; HRMS (EI) m/z calcd M + 1 for C19H15O7 355.0812, found
355.0816.
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CHAPTER 3:  SYNTHESIS OF CHROMAN ALDEHYDES THAT INHIBIT HIV
INTRODUCTION
Since 1983 the Human Immunodeficiency Virus (HIV) / AIDS has been a
worldwide health problem.1 At the end of 2009, an estimated 33.3 million people were
living with HIV, a retrovirus in the lentivirus subfamily. HIV-1 is the more pathogenic of
the two known HIV types.2 Before the first anti-HIV drug—zidovudine3 (AZT) (Figure
1)—was brought to market in 1987, infection with HIV quickly led to AIDS and then
death. Now there are 253 approved drugs belonging to seven different classes of antiviral
drugs that are used in combination therapy known as highly active antiretroviral therapy
(HAART).4 With this therapy, HIV is now a chronic infection that can be controlled for
years. However, there is still no vaccine that prevents the infection or therapy that cures
the disease and eliminates all infectious particles despite substantial research.2 A keyword
search of “HIV” in the ISI Web of KnowledgeSM covering 2009-2011 resulted in 40,916
published papers.
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Figure 1.  Zidovudine, the first drug against HIV
Discovering and developing drugs for HIV is based on knowledge of the viral life
cycle, which is divided into roughly ten different steps: virus-cell adsorption, virus-cell
fusion, uncoating, reverse transcription, integration, DNA replication, transcription,
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translation, budding (assembly/release), and maturation.2,4 The 25 anti-HIV drugs are
categorized into seven groups (Table 1) based on the effects the drugs have on the viral
life cycle. These groups are (i) nucleoside reverse transcriptase inhibitors (NRTIs); (ii)
nucleotide reverse transcriptase ininhibitors (NtRTIs); (iii) non-nucleoside reverse
transcriptase inhibitors (NNRTIs); (iv) protease inhibitors (PIs); (v) fusion inhibitors
(FIs); (vi) co-receptor inhibitors (CRIs); and (vii) integrase inhibitors.4
Table 12: Approved antiretroviral drugs
Approval date
Co-receptor inhibitors (CRIs)
  Maraviroc (UK-427,857, Selzentry®) 06 August 2007
Fusion inhibitors (FIs)
   Enfuvirtide (T20, Fuzeon®) 13 March 2003
Integrase inhibitors
   Raltegravir (MK-0518, Isentress®) 12 October 2007
Reverse transcriptase inhibitors
   Nucleoside/nucleotide analogues (NRTIs/NtRTIs)
      Abacavir (ABC, Ziagen®) 17 December 1998
      Didanonise (ddI, Videx®) 09 October 1991
      Emtricitabine (FTC, Emtriva®) 02 July 2003
      Stavudine (d4T, Zerit®) 24 June 1994
      Lamivudine (3TC, Epivir®) 17 November 1995
      Tenofovir (DF, Viread®) 26 October 2001
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      Zalcitabine (ddc, Hivid®) 19 June 1992
      Zidovudine (AZT, Retrovir®) 19 March 1987
   Non-nucleoside inhibitors (NNRTIs)
      Delavirdine (DLV, Rescriptor®) 4 April 1997
      Efavirenz (EFV, Sustiva®) 17 September 1998
      Etravirine (TMC125, Intelence®) 18 January 2008
      Nevirapine (NVP, Viramune®) 21 June 1996
Protease inhibitors (PIs)
   Amprenavir (AMP, Agenerase®) 15 April 1999
   Atazanavir (ATZ, Reyataz®) 20 June 2003
   Darunavir (TMC-114, Prezista®) 23 June 2006
   Fosamprenavir (GW-433908, Lexiva®) 20 October 2003
   Indinavir (IDV, Crixivan®) 13 March 1996
   Lopinavir (ABT-378, Kaletra® (trade name in combination
         with RTV))
15 September 2000
   Nelfinair (NFV, Viracept®) 14 March 1997
   Ritonavir (RTV, Norvir®) 01 March 1996
   Saquinavir (SQV, Fortovase®, Invirase®) 07 November 1997
   Tipranavir (TPV, Aptivus®) 22 June 2005
Nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine (1) and
nucleotide reverse transcriptase ininhibitors (NtRTIs) target HIV reverse transcriptase at
the catalytic substrate (dNTP) binding site and an allosteric site. NRTIs are converted to
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their activate forms in the cell by kinases, which phosphorylate the 5´-hydroxy group
three times. The resulting triphosphosphates are competitive inhibitors or alternative
substrates during chain elongation, which is terminated by NRTIs.4
Tenofovir (2) (Figure 2) is the only approved nucleotide reverse transcriptase
inhibitor (NtRTI). The compound contains a phosphonate group that is analogous to a
phosphate group, so 2 requires only two phosphorylation steps before is converted to the
active metabolite. Also, the phosphonate cannot be cleaved by esterases as is the case
with phosphates. Like NRTIs, 2 acts as a competitive inhibitor or an alternative
substrate.4
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Figure 2. Tenofovir, a NtRTI
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as Nevirapine (3)
(Figure 3) interact with an allosteric binding site on HIV-1 reverse transcriptase, which
blocks the activity of the enzyme. NNRTIs are integral to the HAART therapies for
patients new to treatment because the drugs are potent, safe and easy to dose. However,
they become ineffective as reverse transcriptase readily undergoes mutations in the
sequence of amino acids near the allosteric binding site.4
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Figure 3.  Nevirapine, a NNRTI
During the HIV life cycle, viral proteases cleave viral precursor polyproteins to
afford mature functional or structural viral proteins. HIV protease inhibitors (PIs) are
peptidomimetics that contain a key hydroxyethylene group, which is structurally similar
to the peptide linkage(s) in the polyprotein precursor (Figure 4). The PIs bind the active
site of the of the HIV protease, blocking protease activity since the hydroxyethylene bond
cannot be cleaved. Nelfinavir (4) is a PI (Figure 5).4
N
H O
N
O
N
H OH
N
O
Substrate
peptidic bond
Inhibitor
hydroxyethylene bond
Figure 4. The hydroxyethylene group of PIs mimics the peptide bond
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Figure 5.  Nelfinavir, a protease inhibitor
Fusion inhibitors (FIs) and co-receptor inhibitors (CRIs) inhibit viral entry into
cells. Enfuvirtide is the only approved HIV FI. It is a peptide with the same sequence of
amino acids as the residues 643-678 in the HIV-1 envelope precursor glycoprotein
gp160. Cellular serine proteases cleave gp160 to gp120—gp41 heterodimer. Fusion of
the viral envelope with the cell membrane is facilitated by gp41. Enfuvirtide inhibits that
process. This is the only anti-HIV drug that has to be subcutaneously injected.4
During viral entry into cells, the HIV envelope gp120 interacts with human
chemokine receptors CCR5 and CXCR4. This changes the conformation of gp120,
exposing co-receptor binding sites, which are able to bind co-receptors. This is followed
by a conformation change in HIV gp41 and insertion of the fusion peptide into the human
cell. Co-receptor inhibitors (CRIs) prevent the conformation change in gp41 and
subsequently the insertion of the fusion peptide. Maraviroc (5) (Figure 6) is currently the
only approved CRI.4
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Figure 6.  Maraviroc, a co-receptor inhibitor
HIV integrase inhibitors inhibit the integration of viral DNA in to host DNA.2
This process is important for the maintenance of the viral genome, viral gene expression
and replication. Raltegravir (6) (Figure 7) is currently the only approved integrase
inhibitor.4
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Figure 7.  Raltegravir, an integrase inhibitor
New antiviral drugs that act by mechanisms other than those of the 25 approved
drugs are needed because of rapidly developing drug-resistance in HIV and drug
toxicity.2 The development of most of the approved antiretrovirals was guided by well-
characterized compounds with an expected interaction within the viral lifecycle such as
the nucleoside analogues.6 However, many HIV patients who were administered these
synthetic drugs developed various side effects such as anemia from AZT (1).7 Plant based
traditional medicines have attracted interest since they are known to be non-toxic by long
practical experience.6,7 As a result of a concerted effort to identify natural products that
inhibit HIV, many useful natural product leads have been reported.8 Several small
molecular weight natural products have been discovered that inhibit viruses.9
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Lawinal (8) (Figure 8) is a flavonoid antiviral containing an aldehyde. It was
isolated from the roots of Desmos spp., which are native to southern Asian countries and
used as folk medicines in China.10 Lawinal was evaluated for inhibition of HIV
replication in H9 lymphocyte cells, and demonstrated potent anti-HIV activity with an
ability to inhibit 50% of HIV replication (EC50) value at 2.30 µg/mL and a therapeutic
index (TI) of 45.2. Also isolated and evaluated was the related chalcone 2-methoxy-3-
methyl-4,6-dihydroxy-5-(3´-hydroxy)-cinnamoylbenzaldehyde (7).10 Remarkably, its
anti-HIV activity was highly potent with the EC50 value at 0.022 µg/mL and a large TI
(489). Compound 7 is an excellent lead compound for further anti-HIV drug
development.10 As part of an effort to identify useful antiviral agents,11,12 we synthesized
chroman aldehydes related to 7 and 8. Compound 9 (Figure 9) is an example of a
synthetic analogue of 7.
CHO
OMeHO
OH
MeO
HO
O
CHO
OH
Me
OHO
7 8
Figure 8.  Structures of small molecule antiviral agents from Desmos spp.
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Figure 9. A synthetic analogue of 7
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The structure of chalcone 7 is interesting since the ketone group is able to chelate
to each of the three hydroxy groups in turn, which gives stability to the enol form and
makes the conceivable diketo form 7a (Figure 10) or the cyclic hemiketal forms 7b and
7c less favorable.9
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Nakagawa-Goto and Lee synthesized 7 from commercially available 2,4,6-
trihydroxybenzaldehyde in six steps without using protecting groups (Scheme 1).13
Aldehyde 10 was reduced with sodium cyanoborohydride (NaBH3CN) under acidic
conditions to 2,4,6-trihydroxytoluene, followed by Friedel-Crafts acylation with Ac2O in
the presence of BF3⋅Et2O to obtain ketone 11. Trimethylsilyldiazomethane (TMSCHN2)
was used to effect monomethylation to give 12, which was formylated with
dichloromethyl methyl ether (Cl2CHOCH3) in the presence of TiCl4 to yield 13.
Monobenzoate 14 resulted from treatment of 13 with benzoyl chloride, pyridine and
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DMAP. The Baker—Venkataraman rearrangement of 14 was accomplished with KOH in
pyridine.
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Scheme 1.  Total synthesis of an anti-HIV chalcone from genus Desmos
 A structural unit that is common in natural products is the 2,2-
dimethylbenzopyran motif, which is considered a privileged structure.5,14 The term
privileged structure was first proposed by Evans to describe special structural types that
bind to multiple, unrelated classes of protein receptors as high affinity ligands.14,15
Typical of privileged structures, the dimethylpyran units are rigid, polycylic heteroatomic
systems that are able to hold various substituents in a well-defined three-dimensional
space.14,16 The analogue, compound 9, contains a dimethylpyran unit.
Three examples of anti-viral natural products that contain the 2,2-
dimethylbenzopyran unit are shown in Figure 11. (+)-Calanolide A (15), a phloroglucinol
derivative, was isolated from Calophyllum lanigerum, a tropical rainforest tree, through a
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screening program by the U.S. National Cancer Institute (NCI).17 The compound is
classified as an NNRTI, but its HIV sensitivity/resistance profile is different from the
approved NNRTIs.2 Mallotochromene (16), another phloroglucinol derivative, was
isolated from the pericarps of Mallotus japonicus and shows strong anti-reverse
transcriptase activity.6 Fuscin (17) was isolated from the soil fungus Oidiodendron
griseum.18 It showed competitive inhibition of the binding of macrophage inflammatory
protein (MIP)-1α to human CCR5 with an IC50 value of 21 µM in the scintillation
proximity binding assay.19,18
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Figure 11.  The 2,2-dimethylbenzopyran motif in anti-HIV-1 natural products
We synthesized chroman analogues of anti-HIV compound 7 during the course of
a collaborative project with Iowa State University Veterinary Medicine researchers. They
were interested in rottlerin (18) (Scheme 11) and synthetic derivatives of 18 for structure-
activity relationship (SAR) studies since it was a lead compound for the treatment of
Parkinson’s Disease. Rottlerin has been isolated from Mallotus philippensis (Kamala
Tree).20 The compound is a chalcone and tetrahydroxy derivative of 16.
A planned route to 18 involved the disconnection shown in Scheme 11. The
methylene bridged phloroglucinol dimer could come from the 1,2-addition of the anion of
tris-O-protected 2,4,6-trihydroxytoluene (19) with chroman aldehyde 20. This route was
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unsuccessful. However, our efforts resulted in the synthesis of antiviral chroman
aldehydes related to 7 and 8.
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Scheme 2. A retrosynthesis of rottlerin (18)
RESULTS AND DISCUSSION
Our initial synthetic plan for rottlerin was based on the tetracyclic, symmetrical
intermediate 21 (Scheme 3), which could be derived from the known phloroglucinol
dimer (20),21 which was made from 2,4,6-trihydroxybenzaldehyde (21) and
phloroglucinol (22). Two sequential Friedel-Crafts acylations of 21 were expected to
occur, one on each aromatic ring. Sequential alkylations would then produce fully
substituted aromatic rings. Mixtures of compounds with different substitution patterns
were expected. However, after removing the acetal carbons, the number of compounds in
the mixture would diminish because of the symmetrical nature of the phloroglucinol
dimer core. For example, isomers 23 and 24 (Scheme 4) can both be transformed into
rottlerin after cleavage of the acetal bridges. Other isomers—those having the wrong
pairing of acyl group and alkyl group on the same ring—would also form, which would
have been acceptable and even desirable for the SAR studies.
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Scheme 3.  The original synthetic plan for rottlerin
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Scheme 4.  The symmetrical core simplifies the mixture after ring cleavage
The key intermediate (21) was made by treating compound 20 with CsF and
dibromomethane in boiling DMF for three hours. The best yield was 31%. Diminishing
yields resulted when more than 900 milligrams of 20 were used. Compound 21
decomposed under Friedel-Crafts conditions.  The aromatic rings could be brominated
and the phenols could be acetylated, but we could not make carbon-carbon bonds to the
phloroglucinol core.
After the initial plan failed, the disconnection shown in Scheme 2 was examined.
The 2,2-dimethylbenzopyran aldehyde 20 was required. Methods to prepare benzopyrans
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include Clemmensen reduction of 2,2-dimethylchromanones,22 addition of methyl
magnesium iodide to dihydrocoumarins,23 and condensation of phenols with 2-methylbut-
3-en-2-ol in an aqueous citric acid solution.24 The starting materials used in the first two
methods must be prepared.25 The third method uses commercially available starting
materials and mild conditions, but the condensation between the five-carbon alcohol and
phloroglucinol gave only 18.5% yield.24
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Scheme 4.  Synthesis of the key intermediate
 Banerji developed a convenient one-step synthesis of 2,2-dimethylchromans from
the nuclear isoprenylation of phenols with isoprene (26) (Scheme 5) 26. The reaction with
phloroglucinol (22) gave 2,2-dimethylchroman-5,7-diol (27) in 50% yield. The reaction
is catalyzed by Amberlyst 15®, a macroreticular sulfonic acid cation exchange resin.
Concerning the procedure, to a boiling slurry of Amberlyst 15 and 22 in THF, 26 in
heptane was added over 2 hours, heated for 30 minutes and then cooled, filtered and
purified. When performed in this manner, starting material was returned.
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22 26 27
Scheme 5.  Amberlyst 15 catalyzed prenylation of phloroglucinol
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Ahluwalia’s25 conditions employed a catalytic amount of orthophosphoric acid
and he obtained a 70% yield of three products: 27, 28, and 29 in the ratio of 5 : 4 : 5,
respectively (Figure 12). In this procedure, to an acidic slurry of 22 and orthophosphoric
acid in light petroleum at 30-35 ºC, was added 26 in light petroleum over 2 hours, stirred
for two hours, then worked up and purified. When performed in this manner, starting
material was returned. By switching the solvent to THF and boiling for 12 hours, the
yield of 27 was 30%. Compounds 28 and 29 were not observed.
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Figure 12.  Products from the orthophosphoric acid catalyzed isoprenylation of 22
Modifying Banerji’s conditions (Scheme 6) by adding three equivalents of
isoprene all at once and then boiling for 12 hours, a mixture of 27 and 30 formed.
Filtering off the Amberlyst 15 and then treating the mixture with 5% citric acid in boiling
water24 produced 27 in a 60% yield over two steps. Switching the solvent to 1,4-dioxane
and boiling for 17 hours resulted in a one-pot reaction that produced 27, 28, and 29 in
69%, 4.8%, and 5% yields, respectively. The reaction was successful on a multi-gram
scale.
As shown in Scheme 7, acetylation of 27 with acetic anhydride afforded a mixture
of 31, 32 and 3327 in 86% yield. Chromatography yielded a mixture of 31 and 32 in 82%
yield and diketone 33 in 4% yield. In early formylation experiments, the mixture of 31
and 32 was treated with TiCl4 and dichloromethyl methyl ether.13,28 Separation of the keto
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aldehydes 35 and 36 could be accomplished by careful chromatography. Later, ketone 32
could be readily separated from 31 by recrystallization. Formylation of 32 with produced
keto aldehyde 36 in 56% yield.
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Scheme 6.  Two-step process for synthesizing 27
Concluding our examination of the disconnection in Scheme 2, treatment of 36
with potassium tert-butoxide and methyl iodide produced dimethoxy keto aldehyde 20 in
10% yield. Byproducts of this reaction were the two mono-O-methylated isomers and
compounds alkylated at the α carbon. Fortunately, compound 20 could be separated from
this complex mixture. Unfortunately, the reaction of 20 with phenyllithium did not give
benzhydrol 37 (Scheme 8).
However, at this juncture our efforts were already directed towards synthesizing
analogues of 7. While searching the literature for methods of formylating acetophenones,
the Nakagawa-Goto and Lee total synthesis of 713 (Scheme 1) came to our attention.
Noticing the similarities between 7 and 35 (Figure 13), we were thankful to have a use
for what was once an unproductive byproduct of the rottlerin synthesis.
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To better understand the effects of structure on activity, we prepared dialdehyde
34 from 27. As shown in Scheme 9, oxidation of 35 with DDQ29 in benzene produced
chromene 38. Benzoylation followed by rearrangement to a β-diketone generated 39.
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Figure 13.  Similarities between 7 and 35
O Me
MeMeO
OMe
OHC
20
MeO
O Me
MeHO
OH
27
Ac2O
BF3-Et2O
86%
O Me
MeHO
OH
32
MeO
O Me
MeHO
OH
31
O
Me
O Me
MeHO
OH
33
MeO
O
Me
+ +
TiCl4, MeOCHCl2
31%
TiCl4, MeOCHCl2
62%
TiCl4, MeOCHCl2
56%
O Me
MeHO
OH
34
O Me
MeHO
OH
35
O
Me
O Me
MeHO
OH
36
MeOCHO
OHC
CHO
OHC
t-BuOK
MeI
10%
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Scheme 8.  Unsuccessful approach to rottlerin
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Scheme 9.  Derivatives of aldehyde 7
Our collaborators in the Department of Microbiology, University of Iowa,
evaluated compounds 20, 33-36, 38 and 39 for their ability to inhibit HIV infectivity in
HeLa37 cells as previously described.30 The concentration of compounds that inhibited
50% and 90% of HIV infectivity (IC50 and IC90) are shown in Table 2. The cytotoxicity of
each compound was tested at the same concentrations. Compound 39 was the most
cytotoxic. All the compounds had inhibitory activity against HIV. Compounds 35, 36 and
38 gave the lowest IC50 values between 30 and 40 µM.
Table 2.
Anti-HIV activity and cytotoxicity of synthesized phloroglucinols
Compound Cytotoxicity (µM) HIV-1 Infection (µM)
 LC50 LC90 IC50 IC90
20 >100 N/D 55.3 >100
33 >100 N/D >100 >100
34 >100 N/D 77.3 >100
35 145 258 30.2 85
36 >100 N/D 39.8 85.6
38 >100 N/D 34.6 98.2
39 82.4 N/D 40.7 86.6
Compound 35 has a TI of about 5, which was significantly smaller than that
reported for Wu for compound 7,10 due to apparently reduced antiviral activity of
compound 35. Diketone 33 was the least active, indicating that an aldehyde moiety is
necessary for good activity. The O-methylated compound 20 showed good activity. The
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closest analogue to 7, diketone 39, exhibited good activity but had the highest
cytotoxicity.
CONCLUSION
We improved a method for synthesizing 2,2-dimethylbenzopyrans, a privileged
structure in natural products. We synthesized a series of chroman aldehydes that are
related to naturally derived aldehydes 7 and 8. The analogues showed anti-HIV activity,
but none showed an IC50 value or therapeutic index comparable to compound 7.
EXPERIMENTAL
Unless otherwise noted, materials were obtained from commercial suppliers and
used without purification. Tetrahydrofuran and diethyl ether were distilled from sodium
and benzophenone. Dichloromethane, benzene and diisopropyl amine were distilled over
calcium hydride. All experiments were performed under an argon atmosphere unless
otherwise noted. Organic extracts were dried over anhydrous magnesium sulfate. Nuclear
magnetic resonance experiments were performed with either a Varian 300 MHz or Varian
400 MHz instrument. All chemical shifts are reported relative to CDCl3 (7.27 ppm for 1H
and 77.23 ppm for 13C), unless otherwise noted. Coupling constants (J) are reported in Hz
with abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. High
resolution mass spectra were recorded on a Kratos model MS-50 spectrometer. Standard
grade silica gel (60 Å, 32-63 µm) was used for flash column chromatography.
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Key intermediate 21: An oven dried 50 mL round bottom flask was fitted with a stir bar
and charged with the phloroglucinol dimer 20 (900 mg, 3.41 mmol), anhydrous DMF (12
mL), anhydrous CsF (3.23 g, 21.25 mmol), and dibromomethane (592 µL, 7.16 mmol).
The flask was fitted with a heat exchanger and heated for 3 h. The dark brown residue in
the flask was diluted with ethyl acetate and water then transferred to a separatory funnel.
It was extracted with ethyl acetate (2x), washed with water (3x), dried over MgSO4, and
concentrated. The product was purified on a column of silica gel with a 30% solution of
ethyl acetate in hexanes to afford 21 (305 mg, 1.09 mmol, 32% yield) as a pale pink
solid, 1H NMR (400 MHz, acetone-d6) δ 8.49 (s, 2H), 6.31 (s, 4H), 5.82 (d, J = 7.6 Hz,
2H), 4.53 (d, J = 7.6 Hz, 2H), 3.91 (s, 2H).
OO O
O
Me
Me Me
Me Me
Me
Me Me
OH
OH
28 29
OHO
OH
Me
Me
27
2,2-Dimethyl-5,7-dihydroxychroman (27):  A 100-mL round bottom flask equipped with
a stir bar was charged with phloroglucinol dihydrate (500.9 mg, 3.97 mmol) followed by
1,4-dioxane (10 mL) and Amberlyst 15 (1.5 g). The resulting mixture was coled to 0 ºC,
and then isoprene (600 mL, 6.0 mmol) was added over 5 min. The reaction vessel was
next equipped with a reflux condenser and boiled. After 17 h, the reaction mixture was
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cooled to rt, filtered through Celite, and the catalyst was washed with hot acetone. The
filtrate was concentrated in vacuo to afford a light yellow solid, which was purified by
column chromatography (hexanes:ethyl acetate = 9:1 to 1:1) to first give a mixture of 28
and 29, which were separated on a silica gel column eluted with toluene. The first
fraction gave 29 (54 mg). The second fraction gave 28 (50 mg). The spectral data
matched the lit.25 The title compound (27) was isolated (536 mg, 69%) as colorless
needles from benzene, mp 163-164 ºC (lit.,12 163-164 ºC). The final fraction contained
recovered phloroglucinol (85.6 mg).
O Me
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Synthesis of 31, 32 and 33 by the acetylation of 27:  A 50-mL round bottom flask with a
stir bar was charged with 3 (1.70 g, 8.77 mmol) followed by AcOH (18.4 mL) and Ac2O
(0.91 mL, 9.65 mmol). The resulting mixture was stirred vigorously and warmed to 40 ºC
until it was homogeneous, and then BF3⋅OEt2 (1.17 mL, 9.21 mmol) was added over 1
min. The resulting red mixture was warmed to 100 ºC. After 10 h at that temperatue, the
mixture was cooled to 0 ºC, quenched with water (10 mL) and pured into a separatory
funnel containing ethyl acetate (25 mL). The phases were separated and the aqueous
phase as extracted with ethyl acetate (3 x 25 mL) and five percent MeOH in ethyl acetate
(5 x 20 mL). The combined organic fractions were washed with water (2 x 25 mL) and
brine (1 x 25 mL), dried over MgSO4, filtered and concentrated. The pale orange solid
was purified by chromatography. Elution with hexanes:ethyl acetate (50:1) gave 6,8-
76
diacetyl-2,2-dimethylchroman-5,7-diol (33) (97.6 mg, 4% yield) as pale yellow needles,
mp 129-130 ºC (lit.27 131-132.5 ºC); 1NMR (400 MHz, CDCl3) δ 2.71 (s, 3H), 2.60 (t, J =
6.8 Hz, 2H), 1.42 (s, 3H). Elution with hexanes:ethyl acetate (5:1) gave a 1:1 mixture (by
1H NMR) of 6-acetyl-2,2-dimethylchroman-5,7-diol (31) and 8-acetyl-2,2-
dimethylchroman (32) (1.68 g, 81.4%). Crystallization from benzene first gave 31 as a
yellow solid, mp 230-230.5 ºC (lit.,27 230 ºC); 1HMR (400 MHz, acetone-d6) δ 5.87 (s,
1H), 2.61 (s, 3H), 2.53 (t, J = 6.8 Hz, 2H), 1.78 (t, J = 6.8 Hz, 2H), 1.30 (s, 6H). The
mother liquor was concentrated and the yellow residue afforded 32 as a yellow solid from
benzene, mp 150-151 ºC (lit.,27 150 ºC); 1H NMR (400 MHz, acetone-d6) δ 5.94 (s, 1H),
2.57 (t, partially obscured, J = 6.8 Hz, 2H), 2.55 (s, 3H), 1.76 (t, J = 6.8 Hz, 2H), 1.37 (s,
6H).
O Me
MeHO
OH
35
O
Me
CHO
6-Acetyl-2,2-dimethyl-8-formylchroman-5,7-diol (35): A 100-mL round bottom flask
equipped with a stir bar was charged with 31 (620.9 mg, 2.63 mmol) followed by
anhydrous CH2Cl2 (50 mL). The resulting mixture was cooled to –78 ºC and then TiCl4
(1.5 mL, 13.4 mmol) was added. This mixture was treated with Cl2CHOMe (2.26 mL, 25
mmol). The resulting red solution was spontaneously warmed to rt and then stirred for 10
h. Then it was cooled to 0 ºC, slowly quenched with ice-cold water (10 mL), stirred for 1
and poured into a separatory funnel. The organic phase was washed with water (3 x 25
mL) and brine (1 x 25 mL), dried over MgSO4, filtered and concentrated in vacuo. The
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residue was purified by column chromatography. Elution with two percent ethyl acetate
and 98% hexanes gave 35 (427.2 mg, 62%) as yellow prisms, mp 102-104 ºC. 1H NMR
(400 MHz, CDCl3) δ 10.00 (s, 1H), 2.69 (s, 3H), 2,56 (t, J = 6.8 Hz, 2H), 1.82 (t, J = 6.8
Hz, 2H), 1.39 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 203.7, 191.8, 171.0, 168.3, 161.8,
103.9, 103.4, 100.3, 77.8, 32.6, 31.5, 26.6, 15.5. HRMS, Calcd for C14H16O5: 264.0998,
Found: 264.1004.
O Me
MeHO
OH
36
MeO
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8-Acetyl-5,7-dihydroxy-2,2-dimethylchroman-6-carboxaldehyde (36): The reaction of 32
under conditions identical to those used for the formylation of 31 provided compound 36
as pale yellow needles, mp 131-134 ºC; 1H NMR (400 MHz, CDCl3) δ 13.23 (s, 1H),
10.18 (s, 1H), 3.63 (s, 3H), 2.60 (t, partially obscured, J = 6.8 Hz, 2H), 1.83 (t, J = 6.8
Hz, 2H), 1.44 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 203.4, 192.3, 169.7, 167.3, 163.0,
104.4, 104.2, 99.6, 78.4, 33.2, 31.1, 26.9, 15.3.
O Me
MeHO
OH
34
CHO
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5,7-Dihydroxy-2,2-dimethylchroman-6,8-dicarbaldehyde (34):  A 100-mL round bottom
flask equipped with a stir bar was charged with 27 (57 mg, 0.295 mmol) followed by
anhydrous CH2Cl2 (10 mL). The mixture was gently warmed and vigorously stirred to
78
fully dissolve the starting material. Next, Cl2CHOMe (160 µL, 1.77 mmol) was added to
the reaction mixture at rt. After cooling to –78 ºC, TiCl4 (98 µL, 0.885 mmol) was added
in drops over 5 min. The resulting red solution was spontaneously warmed to rt and then
stirred for 10 h. It was then cooled to 0 ºC, slowly quenched with ic-cold water (5 mL),
and stirred for 1 h. The CH2Cl2 was then distilled off using a rotary evaporator. The
purplish slurry was dissolved in ethyl acetate (20 mL) and pured into a separatory funnel.
The organic phase was washed with water (3 x 20 mL) and brine (1 x 20 mL) then dried
over MgSO4, filtered and concentrated to give a dark purplish-brown residue. It was
purified by column chromatography (ethyl aceate, hexanes) to give 34 (23 mg, 31%
yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 10.16 (s, 1H), 10.04, (s, 1H), 3.59
(t, J = 6.4 Hz, 2H), 1.82 (t, J = 6.4 Hz, 2H), 1.42 (s, 6H). 13C (100 MHz, CDCl3) δ 192.1
(overlap of 2 Cs), 168.9, 168.1, 163.3, 104.1, 103.7, 100.0, 78.3, 31.4, 26.7, 12.1. HRMS,
Calcd for C13H14O5: 250.08412, Found 250.08458.
O Me
MeMeO
OMe
OHC
20
MeO
8-Acetyl-5,7-dimethoxy-2,2-dimethylchroman-6-carbaldehyde (10): A 50-mL round
bottom flask equipped with a stir bar was charged with 36 (55.3 mg, 0.209 mmol)
followed by THF (2 mL) and t-BuOH (0.5 mL). The resulting mixture was cooled to 0 °C
and then t-BuOK (56.4 mg, 0.502 mmol) was added all at once. MeI (65 µL, 1.05 mmol)
was added in drops over 1 min. The ice bath was removed to allow the resulting yellow
slurry to warm to rt; then it was warmed to 40 °C for 2 h. After cooling to rt, the mixture
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was quenched with water and acidified with 1 N HCl. The mixture was extracted twice
with ethyl acetate. The combined organic layers were washed with brine, dried over
MgSO4 and concentrated. The residue was purified by column chromatography on SiO2
(ethyl acetate-hexanes) to obtain 20 (6.3 mg, 10%).  1H NMR (400 MHz, CDCl3) δ 10.23
(s, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 2.73 (t, J = 6.4 Hz, 2H), 1.82 (t, J = 6.4 Hz, 2H), 1.36
(s, 6H).
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6-Acetyl-2,2-dimethyl-8-formylchromen-5,7-diol (38): A slurry of 7 (75.9 mg, 0.287
mmol) and DDQ (71.7 mg, 0.316 mmol) in benzene (3 mL) was heated at 100 ºC in a
sealed tube for 20 h. Then the mixture was filtered through Celite. Benzene was used to
rinse the reaction flask and wash the filterpad. The filtrate was concentrated, and then the
residue was purified by column chromatography on SiO2 to obtain 38 (1.6 mg, 2%). 1H
NMR (400 MHz, CDCl3) δ 13.15 (s, 1H), 10.20 (s, 1H), 6.61 (d, J = 10 Hz, 1H), 5.51 (d,
J = 10 Hz, 1H), 2.68 (s, 3H), 1.55 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 203.6, 192.7,
178.3, 170.9, 164.6, 124.8, 115.4, 104.8, 104.3, 101.1, 80.7, 33.2, 28.8. HRMS Calcd for
C14H14O5: 262.0841, Found 262.0846.
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6-(1,3-Dioxo-3-phenylpropyl)-2,2-dimethyl-8-formylchroman-5,7-diol (39): Potassium
tert-butoxide (100 mg, 0.82 mmol) was suspended in t-BuOH (1.5 mL) and anhydrous
THF (5 mL), and then cooled to –10 ºC. A solution of 35 (58.1 mg, 0.22 mmol) in
anhydrous THF (5 mL) was added. After stirring at –10 ºC for 15 min, benzoyl chloride
(0.512 mL, 0.44 mmol) was added. The ice bath was removed, and the mixture warmed
to rt. Then the mixture was heated at reflux for 5 h. After cooling to rt, the mixture was
quenched with water and acidified with 1 N HCl. The mixture was extracted twice with
ethyl acetate. The combined organic layers were washed with brine, dried over MgSO4
and concentrated. The residue was purified by column chromatograpy on SiO2 (ethyl
acetate:hexanes = 1:19) to obtain 39 (17 mg, 21% yield) as a mixture of tautomers. 1H
NMR (300 MHz, CDCl3) δ 10.03 (s, 1H, CHO, for enol form), 9.95 (s, 0.73H, CHO, for
1,3-diketo form), 7.97-7.92 (m, ArH, for both forms), 7.65 (s, olefin for enol form), 1.40
(s, 6H, 2 x CH3, for enol form) 1.39 (s, 6H, 2 x CH3, for 1,3-diketo form); HRMS Calcd
for C21H20O6: 368.126, Found 368.126.
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CHAPTER 4:  SELECTIVE METALATION OF 4,6-DIBROMORESCORINOL
DIMETHYL ETHER WITH LiTMP
INTRODUCTION
In Wyatt and Warren’s 2007 textbook,1 they begin the chapter by covering the
ortho strategy for aromatic compounds with a look at traditional methods:  the Friedel-
Crafts reaction, the Fries rearrangement and the Claisen rearrangement. Most of the
chapter is dedicated to ortho-lithiation—a powerful synthetic technique. The introduction
herein is organized similarly, leading up to the unexpected selectivity in the ortho-
lithiation of 4,6-dibromoresorcinol dimethyl ether (1) with lithium tetramethylpiperidide
(LiTMP).
MeO OMe
Br Br
1
Traditional methods of ortho substitution
Making carbon-carbon bonds to aromatic rings by electrophilic substitution
reactions using ortho and para or meta directing groups is taught to organic chemists
early in their training.1,2 When working with activated aromatic rings, mixtures of ortho
and para substituted products are formed. This is acceptable at an early stage in a
synthetic route since large scales can be used, separation is usually trivial and uses can be
found for the unwanted isomer. A large activating group can direct substitution to the
para position. However, making high yields of ortho compounds is difficult.
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Scheme 1.  Acylation of anisole
Friedel-Crafts acylation of simple aromatic ethers such as anisole (2, Scheme 1)
predominately gives the para ketone 3.3 Compound 4 must give the ortho product 5
(Scheme 2) since the electrophile is tethered to the aromatic ring.4
O OH
O
O
O
PPA
4 5
94%
Scheme 2.  An ortho product from the Friedel-Crafts acylation
The Fries reaction5 converts phenol esters 7, Scheme 3, to ortho- or para-hyroxy
ketones upon treatment with aluminum chloride. In polar solvents such as nitrobenzene
(PhNO2), the major product is para-substituted 6. However, the ortho-products (8) are
obtained selectively when 7 is heated to high temperatures either neat or in non-polar
solvents. During the process,1 the Lewis acid catalyzes the cleavage of the ester bond to
form an ion pair consisting of an acylium ion and a metal complex of the phenol.
Electrostatic interactions hold the pair close together when the reaction is performed
without solvent or with a non-polar solvent, which leads to ortho-substitution. The pair
separates in polar solvents, leading to normal Friedel-Crafts selectivity.
OH
R
O
O R
O
OH
R
O
AlCl3
PhNO2
AlCl3
165 ºC
6 7 8
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Scheme 3.  Fries rearrangement
Three positions in m-cresol (9) Scheme 4 are activated. Friedel-Crafts acylation of
methyl ether 10 produced ketone 11 almost exclusively.1 The Fries reaction of the simple
meta-substituted phenol ester 12 (Scheme 5) resulted in a 95% yield of compound 13.6
Me OH
9
Me OMe Me OMeAc2O
AlCl3
1110
Me
O
Scheme 4.  Acylation of m-cresol methyl ether
Me O Ac2O
165 ºC
12
Me
O
Me OH
13
Me
O
Scheme 5.  Fries reaction of a meta-substituted phenol ester
The Claisen rearrangement (CR)7 produces ortho-substituted phenols (Scheme 6)
through a [3,3] sigmatropic rearrangement of allyl aryl ethers 14 to give intermediates
(15) that are the “keto form” of new phenols 16. The reactions are regiospecific in the
allyl portion. However, the CR of resorcinol derivatives 17 (Scheme 7) gives mixtures of
isomers 18 and 19.8
[3,3]
OH
14 16
R
O
R
O
RH
15
Scheme 6. The Claisen rearrangement
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MeO O MeO OH MeO OH
+
17 18   48% 19   32%
∆
Scheme 7.  The CR of 17 gave a mixture8
Ortho-lithiation
 Lithium is introduced ortho to a ring substituent that is already present, Scheme
8,1 and the process is called ortho- or directed lithiation. It has taken over classical
electrophilic aromatic substitution as the primary way of making regiospecifically
substituted aromatic rings.9
XR
Li
XR
20 21 22
XR
E
BuLi E+
Scheme 8.  General ortho-lithiation reaction
Gilman10 and Wittig11 conducted the first lithiations in 1939 and 1940,
respectively. Gilman treated anisole (Scheme 9) with n-butyllithium in ether for twenty
hours followed addition of powdered carbon dioxide to yield 24 in 19% yield. The
methoxy group is the ortho directing group and is called the ‘ortho-director.’1 The lone
pair on the oxygen atom coordinates to the organolithium reagent.
OMe OMe
2 24
CO2H
1. BuLi
2. CO2
Scheme 9.  Ortho-lithiation of anisole
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The Fries and Claisen rearrangements require an oxygen atom ortho to the site
where substitutions will occur. On the other hand, ortho-lithiation works well not only
with oxygen atoms, but also with a variety of other directing groups. This makes the
reaction much more versatile than the traditional methods.1
Gschwend and Rodriguez reviewed the lithiation reaction in 1979.12 In their
discussion of the mechanism, they note the importance of distinguishing between the two
types of metalating agents, lithium alkyls or aryls and lithium dialkylamides. The first
type, lithium alkyls and lithium aryls, are oligomers in solution and they are Lewis acids
that can coordinate with Lewis bases such as amines and ethers. Coordination
depolymerizes the alkyl lithiums, which makes them kinetically more basic. Therefore,
tetrahydrofuran is the most used solvent since it generates the active lithiating species by
coordination and depolymerization of the oligomers.
The second type of lithiating agent—lithium dialkylamides—has less Lewis-acid
character than the first type. Lithium dialkylamides are also thermodynamically less basic
than alkyl or aryl lithiums as the pKa of secondary amines is ~30 and the pKa of n-butane
is 45-50.
When alkyl or aromatic lithiums are used, the first step in the reaction is
coordination of the Lewis-acidic metal with the lone pair in the substrate heteroatom.12
The next step is abstraction of the ortho hydrogen atom by the carbanionic portion of the
lithiating agent, which generates the lithiated product. Other factors such as inductive
effects of heteroatoms or substituents are also important in these reactions. Therefore,
Gschwend and Rodriguez proposed that the process occurs by two limiting mechanisms:
1. “coordination only” mechanism
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2. “acid-base” mechanism
In the ortho-lithiation of anisole (Scheme 9), both effects contribute. Fluorine is
unable to coordinate alkyl lithiums, yet it is an excellent ortho director.1 Therefore, only
the acid-base mechanism is operational when fluorobenzene is the substrate. All of the
aryl halides are good ortho directors. Lithium dialkylamides are used to lithiate bromo- or
iodobenzenes because metal-halogen exchange occurs instead when alkyl lithiums are
used. Since halogens are non-coordinating and lithium diallkylamides are not Lewis
acidic, the acid-base mechanism is operational during the ortho-lithiation of the
halobenzenes.
As an intermediate towards a natural product total synthesis, compound 25 was a
target in our lab (Scheme 10). The planned route required 4,6-dibromoresorcinol
dimethyl ether (1), which was prepared by brominating commercially available 1,3-
dimethoxybenzene.13 The next step was to employ directed ortho-lithiation to deprotonate
and then alkylate 1 first at position 2—methyl ether is a strong ortho-directing
group—and then at postion 5—bromine is an ortho-directing group weaker than methyl
ether.9
MeO
OMe
Br
Br
Me
HO
O
Me
MeO
OMe
Br
Br
5
2
25 1
Scheme 10
As previous studies had shown, 1,3-dimethoxybenzene is synthetically useful
because of the combined effects of the O-methyl groups to direct lithiation to the 2-
position. 14,15 For example, trapping 2,6-dimethoxyphenyllithium with CO2 is a key step
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in the synthesis of methicillin (Scheme 11).16 On the other hand, there are fewer examples
of the metalation of 1,3-dibromobenzenes.17,18
MeO OMe MeO OMe
Li
MeO OMe
CO2H
H
N
N
S
O
H
CO2H
OMe
OMe O
PhLi CO2
methicillin
Scheme 11.  Metalation of 1,3-dimethoxybenzene used in a total synthesis
RESULTS AND DISCUSSION
At –78 °C in tetrahydrofuran (THF), lithium tetramethylpiperidide (LiTMP)
selectively deprotonated 1 at the position adjacent to the halogens. Trapping the
intermediate with methyl iodide afforded derivative 26 in 96% yield (Scheme 12). A
strong NOE correlation between the aromatic ring hydrogen and the O-methyl groups
supported the structure of 26. Further support of 26 came from dibrominating 2,6-
dimethoxytoluene, which gave a compound with a different proton NMR spectrum than
26.
OMeMeO
BrBr
OMeMeO
BrBr
1. LiTMP
2. MeI
26
Me
1
Scheme 12.  Metalation and alkylation of 1
The reason why the bromines were the more powerful ortho-directing groups is not
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clear. Serwatowski and co-workers19 studied the metalation of 2,5- and 3,5-
dibromoanisole with lithium diisopropylamide at –85 °C. They observed a mixture of
metalation products with a product ratio that was time dependent—a and b were formed
in a ratio of 85:15 when litiation of 3,5-dibromoanisole was carried out for 15 minutes
prior to quenching with DMF, the ratio changed to 70:30 when lithiation was carried out
for 2 hours (Scheme 13).
At temperatures greater than –70 °C, they observed benzyne formation. Hickey and
co-workers also observed benzyne formation—this could be minimized by carefully
controlling the reaction temperature—when they studied the metalation of 3-
bromochlorobenzene on an industrial scale.20
OMe
Br Br
OMe
Br Br
OMe
Br Br
OMe
Br Br
OMe
Br Br
Li
Li
CHO
CHO
LDA
-85 oC, THF
1. DMF
2. H3O+
+
+
a b
Scheme 13.  LDA-mediated metalation of 3,5-dibromoanisole
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Table 1.  Reaction of the anion of 1with representative electrophiles
Electrophile
Methyl Iodide
Br
O
O
OEtBr
O
O
Br
O
Iodine
Entry
1
2
3
4
5
6
7
8
Product
MeO
OMe
Br
Br
OH
MeO
OMe
Br
Br
OH Br
OMe
MeO
Br
Br OH
MeO
OMe
Br
Br O
OEt
MeO
OMe
Br
Br
MeO
OMe
Br
Br
Me
MeO
OMe
Br
Br
MeO
OMe
Br
Br
I
OH
Yield, %
26
27
28
29
30
31
96
98
0
0
72
55
53
75
OMeMeO
BrBr
OMeMeO
BrBr
E
LiTMP
E+
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The metalation of 1 did not lead to the desired product. However, the reaction was
regioselective. Therefore, we reacted the anion of 1 with representative electrophiles.
This work is described in Table 1. As the results illustrate, some compounds with acidic
α-protons—6-methyl-5-hepten-2-one (entry 3) and ethyl bromoacetate (entry 4)—did not
afford the desired products, presumably due to anion exchange. Steric hindrance between
the electrophile and the bromine atoms of the anion of 1 likely leads to this exchange
rather than nucleophilic addition to the carbonyl group. Fortunately, the anion of 1 reacts
effectively with iodine, alkyl halides, and both aliphatic and aromatic aldehydes.
Trost and Saulnier21 showed that the steric demand of the t-butyldimethylsilyl
group in c (Scheme 14) directs metalation away from the positions ortho to the phenolic
oxygen bearing the protecting group. The reaction of c with t-BuLi selectively gives the
4-lithio anion d that reacts effectively with electrophiles.
MeO OMe
OTBS
MeO OMe
OTBS
Li
MeO OMe
OTBS
E
t-BuLi E+
c d
Scheme 14.
Serwatowski and co-workers19 found that with 2,5-dibromoanisole (e) (Scheme 15)
the regiochemistry of metalation is controlled by the bromine at position 2. Treatment of
e with LDA generated the 3-lithio species f that was quenched with DMF to afford
aldehyde g in a 47% yield. They rationalized that deprotionation occurred at the 3-
position due to the long-range inductive effect of the methoxy group, and they believed
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sterics between the bromine and the methoxy group forced the methoxy group into the
anti-oriented conformer with respect to the adjacent bromine. This hindered metalation at
the position ortho to the methoxy group.
Br
OMe
Br Li
OMe
Br CHO
OMe
e f
Br Br Br     LDA
-85 oC, THF
1. DMF
2. H3O+
g
Scheme 15.
Schlosser and co-workers invoked an effect termed ‘steric buttressing’ to
rationalize the novel metalation reaction shown in Scheme 16.22 The superbasic LiC-
KOR mixture of stoichiometric amounts of butyllithium and potassium tert-butoxide
metalates benzotrifluoride only at the ortho position. However, triethyl[(2-
trifluoromethyl)phenyl]silane (h) was metalated only at the 4-position.
Et3Si Et3Si
Li
CF3 CF3BuLi, t-BuOK
h
Scheme 16.  Schlosser’s evidence of steric buttressing
Since we found no reports of the reaction of 1,3-dimethoxybenzene with LiTMP, a
possible explanation for the observed result is that LiTMP does not readily deprotonate
1,3-dimethoxybenzene at low temperatures. Treatment of 1,3-dimethoxybenzene with
LiTMP under the conditions used to deprotonate 1, followed by addition of
benzaldehyde, afforded a 40% yield of the benzhydrol. Significantly, a competition
experiment using one equivalent of 1,3-dimethoxybenzene and one equivalent of 1,3-
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dibromobenzene with one equivalent of LiTMP, using conditions employed to
deprotonate 1 followed by quenching with benzaldehyde, produced only the adduct with
1,3-dibromobenzene (Scheme 17). In view of this experiment, it is unlikely that steric
buttressing plays a large role in the observed selectivity with 2.
MeO OMe Br Br
Br Br
PhHO
1. LiTMP
2. PhCHO
+
Scheme 17.  Competition experiment
CONCLUSION
The metalation of 1 is regioselective. The anion is stable enough at –78 °C to
react with a variety of electrophiles. Regardless of the origin of the regioselectivity, this
selective deprotonation will likely find a number of applications in the synthesis of
resorcinol-based natural products.
EXPERIMENTAL
Unless otherwise noted, materials were obtained from commercial suppliers and
used without purification. Tetrahydrofuran and diethyl ether were distilled from sodium
and benzophenone. Dichloromethane, benzene and diisopropyl amine were distilled over
calcium hydride. All experiments were performed under an argon atmosphere unless
otherwise noted. Organic extracts were dried over anhydrous magnesium sulfate. Nuclear
magnetic resonance experiments were performed with either a Varian 300 MHz or Varian
400 MHz instrument. All chemical shifts are reported relative to CDCl3 (7.27 ppm for 1H
and 77.23 ppm for 13C), unless otherwise noted. Coupling constants (J) are reported in Hz
with abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. High
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resolution mass spectra were recorded on a Kratos model MS-50 spectrometer. Standard
grade silica gel (60 Å, 32-63 µm) was used for flash column chromatography.
Representative experimental procedure. To a solution of tetramethylpiperidide (326
mg, 0.392 mL, 2.3 mmol) in THF (5 mL) at 0 °C was added n-BuLi (2.5 M in hexane,
0.843 mL, 2.1 mmol). After stirring for 20 min, the flask was cooled to –78 °C. Quickly,
the flask was opened, solid 4,6-dibromoresorcinol dimethyl ether (1; 297 mg, 1.0 mmol)
was added all at once, and the flask was resealed. Compound 1 dissolved to give a
homogeneous mixture, which became a white slurry about 30 min after the addition.
After stirring at –78 °C for a total time of 3 h, a room temperature solution of allyl
bromide (607 mg, 0.424 mL, 5.0 mmol) in THF (1 mL) was added over 1 min. The
resulting mixture was stirred at –78 °C for 30 min and then the ice bath was removed.
After warming to r.t., the reaction mixture was poured into saturated NH4Cl solution and
the aqueous layer was extracted twice with diethyl ether. The combined organic layers
were dried (brine and MgSO4) and concentrated. The residue was purified by silica gel
column chromatography (EtOAc—hexane, 1:99) to give 27 (329 mg, 98%) as a white
solid.
MeO OMe
Br Br
Me
1,3-Dibromo-2-methyl-4,6-dimethoxybenzene (26): Purification by column
chromatography on silica gel (EtOAc–hexane, 1:20) gave the title compound 26 in 96%
yield, which crystallized from benzene–hexane (3:1) as white needles; mp 168–169 °C
(Lit.18 168–169 °C). 1H NMR (400 MHz, CDCl3): δ = 6.42 (s, 1 H), 3.91 (s, 6 H), 2.62 (s,
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3 H). 13C NMR (100 MHz, CDCl3): δ = 155.7, 139.2, 105.7, 94.8, 56.5, 24.2. HRMS (EI):
m/z calcd for C9H10Br2O2: 309.9027; found: 309.9032. Anal. Calcd for C9H10Br2O2: C,
34.87; H, 3.25. Found: C, 34.85; H, 3.20.
OMe
MeO
Br
Br
2-Allyl-1,3-dibromo-4,6-dimethoxybenzene (27): Purification by column
chromatography on silica gel (EtOAc–hexane, 1:99) gave the title compound 27 in 98%
yield, which crystallized from hexane as white plates; mp 67–68 °C. 1H NMR (400 MHz,
CDCl3): δ = 6.45 (s, 1 H), 5.96–5.86 (m, 1 H), 5.12–5.07 (m, 2 H), 3.92 (s, 6 H), 3.87 (d,
J = 8.00 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ = 155.9, 140.2, 133.1, 116.5, 105.8,
95.3, 56.5, 40.9. HRMS (EI): m/z calcd for C11H12Br2O2: 335.9184; found: 335.9189.
OMe
MeO
Br
Br OH
(2,6-Dibromo-3,5-dimethoxyphenyl)(phenyl)methanol (28): Purification by column
chromatography on silica gel (EtOAc–hexane, 1:9) gave the title compound 28 in 72%
yield, which crystallized from benzene–hexane (1:3) as white prisms; mp 147–148 °C. 1H
NMR (400 MHz, CDCl3): δ = 7.38–7.25 (m, 5 H), 6.80 (d, J = 11.2 Hz, 1 H), 6.55 (s, 1
H), 3.94 (s, 6 H), 3.87 (d, J = 11.2 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ = 156.2,
141.5, 141.4, 128.1, 126.9, 125.4, 96.3, 96.3, 76.5, 56.6. HRMS (EI): m/z calcd
C15H14Br2O3: 401.9289; found: 401.9294.
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OMe
MeO
Br
Br OH Br
(2-Bromophenyl)(2,6-dibromo-3,5-dimethoxy- phenyl)methanol (29): Purification by
column chromatography on silica gel (EtOAc–hexane, 1:9) gave the title compound 29 in
55% yield, which crystallized from benzene–hexanes (3:1) as a white powder; mp
190–191 °C. 1H NMR (400 MHz, CDCl3): δ = 7.58 (d, J = 8.0 Hz, 1 H), 7.37 (d, J = 8.0
Hz, 1 H), 7.22 (t, J = 8.0 Hz, 1 H), 7.14 (t, J = 8.0 Hz, 1 H), 6.75 (d, J = 8.0 Hz, 1 H),
6.54 (s, 1 H), 3.93 (s, 6 H), 3.50 (d, J = 8.0 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ =
156.2, 139.8, 139.2, 133.4, 129.8, 129.3, 126.8, 123.7, 105.8, 96.5, 77.2, 56.7. HRMS
(EI): m/z calcd for C15H13Br3O3: 367.9446; found: 367.9450.
OMe
MeO
Br
Br OH
1-(2,6-Dibromo-3,5-dimethoxyphenyl)butan-1-ol (30): Purification by column
chromatography on silica gel (EtOAc–hexane, 1:9) gave the title compound 30 in 53%
yield as a pale-yellow viscous liquid which solidified upon drying in vacuo; mp 73–74
°C. 1H NMR (400 MHz, CDCl3): δ = 6.44 (s, 1 H), 5.54–5.48 (m, 1 H), 3.89 (s, 6 H),
3.27 (d, J = 8.0 Hz, 1 H), 2.12–2.03 (m, 1 H), 1.87–1.78 (m, 1 H), 1.65–1.53 (m, 1 H),
1.41–1.28 (m, 1 H). 13C NMR (100 MHz, CDCl3): δ = 155.9, 141.9, 95.7, 75.9, 56.6,
37.2, 19.2, 13.9. HRMS (EI): m/z calcd for C12H16Br2O3: 367.9446; found: 367.9450.
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MeO
Br
Br
I
2,6-Dibromo-1-iodo-3,5-dimethoxybenzene (31): Purification by column
chromatography on silica gel (EtOAc–hexane, 1:9) gave the title compound 31 in 75%
yield, which crystallized from hexanes as white needles; mp 181–182 °C. 1H NMR (400
MHz, CDCl3): δ = 6.57 (s, 1 H), 3.91 (s, 6 H). 13C NMR (100 MHz, CDCl3): δ = 156.3,
112.2, 111.5, 96.9, 56.9. HRMS (EI): m/z calcd for C8H7Br2IO2: 421.7837; found:
421.7845.
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CHAPTER 5.  GENERAL CONCLUSIONS
Chapter 2 describes the efficient syntheses of simple oxygenated xanthones using
an environmentally benign methodology. It is shown that the xanthone nucleus can be
regioselectivly elaborated into an intermediate that is key to the synthesis of
psoroxanthin, a cytotoxic compound. Progress towards the total synthesis of psoroxanthin
is ongoing in our labs.
Chapter 3 describes the syntheses of analogues of an anti-HIV natural product. In
structure activity relationship studies, it was shown that the aldehyde functional group is
important to the anti-HIV properties. An imporoved procedure for the synthesis of the
2,2-dimethylbenzopyran unit was also developed.
Chapter 4 describes the unexpected regioselectivity in the metaltion of 4,6-
dibromorescorinol dimethyl ether with LiTMP. It occurred between the bromines.
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